10/522986 NITROOXYALKYL SUBTD ESTERS

STN

Connecting via Winsock to STN

Correct generic formula
Mel 9/19/2007

Welcome to STN International! Enter x:x

LOGINID:SSPTAMLL1621

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUL 02	LMEDLINE coverage updated
NEWS 3	JUL 02	SCISEARCH enhanced with complete author names
NEWS 4	JUL 02	CHEMCATS accession numbers revised
NEWS 5	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 6	JUL 16	CAplus enhanced with French and German abstracts
NEWS 7	JUL 18	CA/CAplus patent coverage enhanced
NEWS 8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9	JUL 30	USGENE now available on STN
NEWS 10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 11	AUG 06	BEILSTEIN updated with new compounds
NEWS 12	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 13	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 14	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 15	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 16	AUG 27	USPATOLD now available on STN
NEWS 17	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 18	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 19	SEP 13	FORIS renamed to SOFIS
NEWS 20	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 21	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 22	SEP 17	CAplus coverage extended to include traditional medicine patents

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 21:58:13 ON 20 SEP 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 21:58:34 ON 20 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 SEP 2007 HIGHEST RN 947584-60-3
DICTIONARY FILE UPDATES: 19 SEP 2007 HIGHEST RN 947584-60-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\2007 cases\10522986\generic.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

```
=> fil stng
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                       260.25     929.76

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                           ENTRY    SESSION
CA SUBSCRIBER PRICE                                       -35.10     -35.10

FILE 'STNGUIDE' ENTERED AT 22:04:42 ON 20 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Sep 14, 2007 (20070914/UP).

=> d his

     (FILE 'HOME' ENTERED AT 21:58:13 ON 20 SEP 2007)

     FILE 'REGISTRY' ENTERED AT 21:58:34 ON 20 SEP 2007
L1             STRUCTURE UPLOADED
L2          15 S L1
L3         274 S L1 SSS FULL
L4             STRUCTURE UPLOADED
L5           1 S L4
L6           3 S L4 SSS FULL
L7           0 S L3  SUB=L6 FULL
L8             STRUCTURE UPLOADED
L9           0 S L8
L10          2 S L8 SSS FULL
L11          0 S L3  SUB=L10 FULL
L12          0 S L10  SUB=L3 FULL

     FILE 'HCAPLUS' ENTERED AT 22:02:54 ON 20 SEP 2007
L13         45 S L3

     FILE 'STNGUIDE' ENTERED AT 22:04:42 ON 20 SEP 2007
```



G1 O,S

G2 A,Cb,Cy,Hy,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 21:58:59 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 464 TO ITERATE

100.0% PROCESSED 464 ITERATIONS 15 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 7988 TO 10572
PROJECTED ANSWERS: 68 TO 532

L2 15 SEA SSS SAM L1

=> d l2 ide 1-15

L2 ANSWER 1 OF 15 REGISTRY COPYRIGHT 2007 ACS on STN
RN 946406-48-0 REGISTRY
ED Entered STN: 07 Sep 2007
CN INDEX NAME NOT YET ASSIGNED
MF C15 H19 Cl2 N5 O7
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 2 OF 15 REGISTRY COPYRIGHT 2007 ACS on STN
RN 946406-25-3 REGISTRY
ED Entered STN: 07 Sep 2007
CN INDEX NAME NOT YET ASSIGNED
MF C17 H26 N2 O9
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 3 OF 15 REGISTRY COPYRIGHT 2007 ACS on STN
RN 946393-63-1 REGISTRY
ED Entered STN: 07 Sep 2007
CN INDEX NAME NOT YET ASSIGNED
MF C17 H19 Br N6 O7
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 4 OF 15 REGISTRY COPYRIGHT 2007 ACS on STN
RN 902126-92-5 REGISTRY

ED Entered STN: 17 Aug 2006
CN 1H-Imidazole-5-carboxylic acid, 2-butyl-4-chloro-1-[[2'-[2-[1-[[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]oxy]ethyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-, 1-[(ethoxycarbonyl)oxy]ethyl ester (CA INDEX NAME)
MF C34 H40 Cl N7 O12
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 5 OF 15 REGISTRY COPYRIGHT 2007 ACS on STN
RN 902126-67-4 REGISTRY
ED Entered STN: 17 Aug 2006
CN 1H-Imidazole-5-carboxylic acid, 1-[[2'-[2-[[[[2-[[2-(nitrooxy)ethyl]thio]ethoxy]carbonyl]oxy]methyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-4-(pentafluoroethyl)-2-propyl- (9CI) (CA INDEX NAME)
MF C29 H28 F5 N7 O8 S
SR CA
LC STN Files: CA, CAPLUS

PAGE 1-A



PAGE 1-B

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 6 OF 15 REGISTRY COPYRIGHT 2007 ACS on STN
RN 902123-62-0 REGISTRY
ED Entered STN: 17 Aug 2006
CN L-Valine, N-[[2'-[2-[1-[[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]oxy]ethyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-N-(1-oxopentyl)- (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H40 N6 O10
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 7 OF 15 REGISTRY COPYRIGHT 2007 ACS on STN
RN 860005-60-3 REGISTRY
ED Entered STN: 12 Aug 2005
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-2-[(1E,3R)-4-(3-chlorophenoxy)-3-hydroxy-1-butenyl]-3,5-dihydroxycyclopentyl]-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester, (5Z)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H36 Cl N O9 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 8 OF 15 REGISTRY COPYRIGHT 2007 ACS on STN
RN 849138-32-5 REGISTRY
ED Entered STN: 25 Apr 2005
CN L-Glutamic acid, 5-[2-[[2-(nitrooxy)ethyl]sulfonyl]ethyl] ester, monohydrochloride (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C9 H16 N2 O9 S . Cl H
SR CA
LC STN Files: CA, CAPLUS, CASREACT, USPATFULL
CRN (849323-92-8)

Absolute stereochemistry.



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 9 OF 15 REGISTRY COPYRIGHT 2007 ACS on STN
RN 838877-30-8 REGISTRY
ED Entered STN: 28 Feb 2005
CN 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (9CI) (CA INDEX NAME)
MF C28 H27 N7 O6 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 10 OF 15 REGISTRY COPYRIGHT 2007 ACS on STN
RN 812681-87-1 REGISTRY
ED Entered STN: 13 Jan 2005
CN Cyclopenta[b]pyrrole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H39 N3 O8 S
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 11 OF 15 REGISTRY COPYRIGHT 2007 ACS on STN
RN 811787-67-4 REGISTRY
ED Entered STN: 12 Jan 2005
CN 6H-Pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid, 9-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]octahydro-10-oxo-, 2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H38 N4 O9
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 12 OF 15 REGISTRY COPYRIGHT 2007 ACS on STN
RN 811787-21-0 REGISTRY
ED Entered STN: 12 Jan 2005
CN L-Proline, N2-[(1S)-1-carboxy-3-phenylpropyl]-N6-[[(nitrooxy)methoxy]carbonyl]-L-lysyl-, 2-[2-[[2-(nitrooxy)ethyl]thio]ethyl] ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H39 N5 O13 S
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 13 OF 15 REGISTRY COPYRIGHT 2007 ACS on STN
RN 183195-07-5 REGISTRY
ED Entered STN: 20 Nov 1996
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, 2-[4-(nitrooxy)butoxy]-2-oxoethyl ester (9CI) (CA INDEX NAME)
MF C20 H20 Cl2 N2 O7
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 14 OF 15 REGISTRY COPYRIGHT 2007 ACS on STN
RN 87055-56-9 REGISTRY
ED Entered STN: 16 Nov 1984
CN Peroxynitric acid, 1-(acetyloxy)-2-nitroethyl ester (9CI) (CA INDEX NAME)
MF C4 H6 N2 O8
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 15 OF 15 REGISTRY COPYRIGHT 2007 ACS on STN
RN 39128-73-9 REGISTRY
ED Entered STN: 16 Nov 1984
CN Peroxynitric acid, 1-[(acetyloxy)methyl]-1-methyl-2-nitroethyl ester (9CI) (CA INDEX NAME)
MF C6 H10 N2 O8
LC STN Files: CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, USPATFULL, USPATOLD



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d his

(FILE 'HOME' ENTERED AT 21:58:13 ON 20 SEP 2007)

FILE 'REGISTRY' ENTERED AT 21:58:34 ON 20 SEP 2007
L1 STRUCTURE UPLOADED
L2 15 S L1

=> s l1 sss full
FULL SEARCH INITIATED 21:59:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 9261 TO ITERATE

100.0% PROCESSED 9261 ITERATIONS 274 ANSWERS
SEARCH TIME: 00.00.02

L3 274 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\2007 cases\10522986\species but generic.str

L4 STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l4
SAMPLE SEARCH INITIATED 22:00:21 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       12 TO ITERATE

100.0% PROCESSED       12 ITERATIONS                                 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           33 TO      447
PROJECTED ANSWERS:               1 TO       80

L5            1 SEA SSS SAM L4

=> s l4 sss full
FULL SEARCH INITIATED 22:00:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      253 TO ITERATE

100.0% PROCESSED      253 ITERATIONS                                 3 ANSWERS
SEARCH TIME: 00.00.01

L6            3 SEA SSS FUL L4

=> d his

     (FILE 'HOME' ENTERED AT 21:58:13 ON 20 SEP 2007)

     FILE 'REGISTRY' ENTERED AT 21:58:34 ON 20 SEP 2007
L1               STRUCTURE UPLOADED
L2            15 S L1
L3           274 S L1 SSS FULL
L4               STRUCTURE UPLOADED
L5             1 S L4
L6             3 S L4 SSS FULL

=> s l3 subset=l6
ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):full
```

10/522986 NITROOXYALKYL SUBTD ESTERS

FULL SUBSET SEARCH INITIATED 22:01:03 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED 3 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L7 0 SEA SUB=L6 SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\2007 cases\10522986\elected species Example2B.str

L8 STRUCTURE UPLOADED

=> d l8
L8 HAS NO ANSWERS
L8 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l8
SAMPLE SEARCH INITIATED 22:01:44 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 12 TO ITERATE

100.0% PROCESSED 12 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 33 TO 447
PROJECTED ANSWERS: 0 TO 0

L9 0 SEA SSS SAM L8

=> s l8 sss full
FULL SEARCH INITIATED 22:01:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 275 TO ITERATE

100.0% PROCESSED 275 ITERATIONS 2 ANSWERS

```
SEARCH TIME: 00.00.01

L10             2 SEA SSS FUL L8

=> s l3 subset=l10
ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):full
FULL SUBSET SEARCH INITIATED 22:02:11 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -        2 TO ITERATE

100.0% PROCESSED         2 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

L11             0 SEA SUB=L10 SSS FUL L1

=> s l10 subset=l3
ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):full
FULL SUBSET SEARCH INITIATED 22:02:36 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -        7 TO ITERATE

100.0% PROCESSED         7 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

L12             0 SEA SUB=L3 SSS FUL L8

=> d his

     (FILE 'HOME' ENTERED AT 21:58:13 ON 20 SEP 2007)

     FILE 'REGISTRY' ENTERED AT 21:58:34 ON 20 SEP 2007
L1                STRUCTURE UPLOADED
L2             15 S L1
L3            274 S L1 SSS FULL
L4                STRUCTURE UPLOADED
L5              1 S L4
L6              3 S L4 SSS FULL
L7              0 S L3  SUB=L6 FULL
L8                STRUCTURE UPLOADED
L9              0 S L8
L10             2 S L8 SSS FULL
L11             0 S L3  SUB=L10 FULL
L12             0 S L10  SUB=L3 FULL

=> file hcaplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             669.30     669.51

FILE 'HCAPLUS' ENTERED AT 22:02:54 ON 20 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 20 Sep 2007 VOL 147 ISS 13
FILE LAST UPDATED: 19 Sep 2007 (20070919/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L13 45 L3

=> d l13 1-45 ibib abs

L13 ANSWER 1 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:907062 HCAPLUS
DOCUMENT NUMBER: 147:277605
TITLE: Preparation of nitrooxy derivatives as α2 adrenergic receptor agonists
INVENTOR(S): Almirante, Nicoletta; Monopoli, Angela; Biondi, Stefano; Ongini, Ennio
PATENT ASSIGNEE(S): Nicox S.A., Fr.
SOURCE: PCT Int. Appl., 146pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007090733	A1	20070816	WO 2007-EP50627	20070123

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-765159P P 20060206
GI



I

AB The α2 adrenergic agonist nitrooxy derivs. of formula A-(X0-ONO2)s and enantiomers and diastereoisomers and pharmaceutically acceptable salts thereof, wherein: s is an integer equal to 1, 2 or 3; wherein A is a precursor of an α2 adrenergic receptor agonists having wider pharmacol. activity and enhanced tolerability. For example, reaction of clonidine hydrochloride with pentafluorophenyl 4-(nitrooxy)butanoate gave I in 94% yield. They can be employed for treating cardiovascular disease, in particular systemic hypertension, renal and chronic liver diseases, inflammatory processes and metabolic syndromes.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:906184 HCAPLUS
DOCUMENT NUMBER: 147:277601
TITLE: Preparation of nitrooxy-comprising derivatives of apraclonidine and brimonidine as α2-adrenergic receptor agonists
INVENTOR(S): Benedini, Francesca; Impagnatiello, Francesco; Biondi, Stefano; Ongini, Ennio; Chong, Wesley Kwan Mung
PATENT ASSIGNEE(S): Nicox S.A., Fr.; Pfizer Inc.
SOURCE: PCT Int. Appl., 54pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007090793	A1	20070816	WO 2007-EP51017	20070202

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-765166P P 20060206
GI



I

AB The present invention relates to α2-adrenergic receptor agonist nitrooxy derivs. of formula A-X1-Y-ONO2 [wherein A = apraclonidinyl or brimonidinyl; X1 = -CO-, -CO2-, -CH(Me)OCO2- or -CH2OCO2-; Y = a bivalent radical] having improved pharmacol. activity and enhanced tolerability. For example, starting from the reaction of 2-bromoethanol with AgNO3, and followed by reaction with triphosgene and brimonidine, gave I in 34% yield. They can be employed for the treatment of ocular diseases, in particular high intraocular pressure and glaucoma (no data).

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:461436 HCAPLUS
DOCUMENT NUMBER: 146:462508
TITLE: Preparation of nitrooxy peptidomimetic renin inhibitors for treating cardiovascular, renal and chronic liver diseases, inflammations and metabolic syndrome
INVENTOR(S): Almirante, Nicoletta; Monopoli, Angela; Ongini, Ennio
PATENT ASSIGNEE(S): Nicox S.A., Fr.
SOURCE: PCT Int. Appl., 73pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007045551	A2	20070426	WO 2006-EP66952	20061002
WO 2007045551	A3	20070607		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2005-727550P P 20051018
OTHER SOURCE(S): MARPAT 146:462508
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention is related to the preparation of renin inhibitors A-(X0-ONO2)n [I; n = 1-2; A = II, III, etc.; N1 = O, OH; N2 = O, NH, N2'; N2' = NH2, OH; with the proviso that at least one of N1 and N2 is a group O or NH able to bind to X0; X0 = X1-Y; X1 = CO, COO; Y = bivalent radical selected from alkylene, cycloalkylene, phenylene, (CR4R6)m-Y2-(CR5R7)q, etc.; m = 0-10; q = 1-10; R4-R7 = independently H, alkyl; Y2 = pyridinylene, piperazinylene, pyrimidinylene, pyridazinylene, etc.] having wider pharmacol. activity and enhanced tolerability. Thus, reacting aliskiren (III; N1 = OH; N2 = NH2) with 4-(nitrooxy)butanoic acid pentafluorophenyl ester in the presence of TEA and DMAP in DMF gave IV in 50% yield. Peptidomimetics I are useful for treating or preventing congestive heart failure, coronary diseases, cardiac insufficiency, left ventricular dysfunction and hypertrophy, cardiac fibrosis, myocardial ischemia, stroke, atherosclerosis, restenosis post angioplasty, renal insufficiency, renal ischemia, renal failure, renal fibrosis, glomerulonephritis, renal colic, ocular and pulmonary hypertension, glaucoma, hypertension, diabetic complications such as nephropathy, vasculopathy and neuropathy, peripheral vascular diseases, liver fibrosis, portal hypertension, metabolic syndrome, erectile dysfunction, complications after vascular or cardiac surgery, complications of treatment with immunosuppressive agents after organ transplantation, hyperaldosteronism, lung fibrosis, scleroderma, anxiety, cognitive disorders (no data).

L13 ANSWER 4 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:259757 HCAPLUS
DOCUMENT NUMBER: 146:317107
TITLE: Preparation of steroid nitrooxy derivatives for use in anti-inflammatory pharmaceutical compositions
INVENTOR(S): Benedini, Francesca; Ongini, Ennio; Guglietta, Antonio; Palop, Daniel; Princep, Marta
PATENT ASSIGNEE(S): Nicox S.A., Fr.; Ferrer Internacional S.A.
SOURCE: PCT Int. Appl., 96pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007025632	A2	20070308	WO 2006-EP7746	20060804
WO 2007025632	A3	20070419		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRIORITY APPLN. INFO.: EP 2005-19155 A 20050902
OTHER SOURCE(S): MARPAT 146:317107
GI



I

AB Steroid nitrooxy derivs., such as R-X-ONO2 [R = sterol moiety, such as triamcinolone acetonide, prednisolone 17-ethylcarbonate or betamethasone 17-valerate; X = linking group consisting of carboxy, carbonate, alkylene, alkenylene and/or phenylene subunits], were prepared for use in topical pharmaceutical formulations for treating skin or mucosal membrane diseases and disorders, such as eczema, erythema, papulation, scaling, erosion, oozing, crusting, pruritis, inflammation, epidermalysis bullosa, erythema, warts, diaper rash, jock itch, ruber lichen planus. These new steroids nitrooxy derivs. have an improved pharmacol. activity and enhanced local tolerability. Thus, steroid nitrooxy derivative I was prepared by an esterification reaction of triamcinolone acetonide with 4-(nitrooxymethyl)benzoic acid using DMAP and EDAC in CH2Cl2.

L13 ANSWER 5 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:118117 HCAPLUS
DOCUMENT NUMBER: 146:190547
TITLE: Pharmaceutical formulation of nitrooxy derivatives of NSAIDS
INVENTOR(S): Gasslander, Ulla; Holmberg, Christina
PATENT ASSIGNEE(S): Nicox S.A., Fr.
SOURCE: PCT Int. Appl., 26pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007012539	A2	20070201	WO 2006-EP63672	20060629
WO 2007012539	A3	20070419		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU,

SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRIORITY APPLN. INFO.: EP 2005-106854 A 20050726
AB The present invention relates to a pharmaceutical formulation comprising: NO-releasing NSAID(s), 1 or more surfactants, a carbonyl scavenger compound, and optionally an oil or semi-solid fat and/ or a short-chain alc. Thus, a capsule contained PABA 3m Poloxamer-407 225, and a nitrooxy derivative of NSAIDS 375 mg.

L13 ANSWER 6 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:14512 HCAPLUS
DOCUMENT NUMBER: 146:121748
TITLE: Prostaglandin derivatives
INVENTOR(S): Benedini, Francesca; Chiroli, Valerio; Chong, Wesley Kwan Mung; Krauss, Achim; Niesman, Michael Ross; Ongini, Ennio
PATENT ASSIGNEE(S): Pfizer Inc., USA; Nicox S.A.
SOURCE: PCT Int. Appl., 64pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007000642	A1	20070104	WO 2006-IB1728	20060619

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-696354P P 20050629
OTHER SOURCE(S): MARPAT 146:121748
GI



I



II

AB Nitrooxy derivs. of prostaglandin esters and amides, such as I [X = NH, O, S; R = X1-ONO2; X1 = linking group which may be composed of alkylene, phenylene, alkenylene and/or amino acid residue with amide, ester, amino, thioether and/or ether linkage], with improved pharmacol. activity and enhanced tolerability were prepared for use in ophthalmic compns. for the treatment of glaucoma and ocular hypertension. Thus, prostaglandin ester II was prepared from tafluprost acid I (X = O, R = H), ferulic acid, and Br-(CH2)4ONO2.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 7 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:768702 HCAPLUS
DOCUMENT NUMBER: 145:188887
TITLE: Preparation of nitrooxy sartan derivatives as angiotensin ii receptor blockers for the treatment of cardiovascular and inflammatory diseases
INVENTOR(S): Almirante, Nicoletta; Nicotra, Alessia; Ongini, Ennio
PATENT ASSIGNEE(S): Nicox S.A., Fr.
SOURCE: PCT Int. Appl., 346pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006079610	A1	20060803	WO 2006-EP50348	20060120

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,

CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-647791P P 20050131
OTHER SOURCE(S): MARPAT 145:188887
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [W = CO, CO2, CH(Me)OCO2, CH2OCO2; Y = bivalent radicals selected from (un)substituted alkylene, cycloalkylene, aryl, etc.; R1 = substituted heterocycle], and their pharmaceutical salts, are prepared as angiotensin II receptor blockers (no data). Thus, e.g., II was prepared by esterification of 4-bromobutanoic acid with pentafluorophenol followed by oxidation to form 4-(nitrooxy)butanoic acid pentafluorophenyl ester which was reacted with 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-5-[(3-nitrooxypropyl)carbonyloxy]methyl-1H-imidazole (preparation given). I can be employed for treatment of cardiovascular and renal diseases and inflammatory processes.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 8 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:14820 HCAPLUS
DOCUMENT NUMBER: 144:260959
TITLE: Identification of a trace colored impurity in drug substance by preparative liquid chromatography and mass spectrometry
AUTHOR(S): Wang, Peng; Shi, Y.-J.; Helmy, Roy; Reamer, Robert; Vailaya, Anant
CORPORATE SOURCE: Analytical Research, Merck Research Laboratories, Rahway, NJ, 07065, USA
SOURCE: Rapid Communications in Mass Spectrometry (2005), 19(24), 3749-3754
CODEN: RCMSEF; ISSN: 0951-4198
PUBLISHER: John Wiley & Sons Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB 6-(Nitrooxy)hexyl-(2z)-4-(acetyloxy)-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoate (enoate 1) was investigated as a novel therapy for pain relief. In a recent manufacturing run at the pilot plant scale, the enoate drug substance was found to have a yellowish color not observed previously. An unknown impurity at trace level was detected by high-performance liquid chromatog. (HPLC) anal. and found to be the primary cause for the color of the drug substance. The colored impurity was enriched by preparative HPLC and structurally elucidated by liquid chromatog./tandem mass spectrometry (LC/MS/MS). It was found that the colored impurity was derived from the product of oxidative dimerization of rofecoxib, an impurity present in the enoic acid intermediate. It was further revealed by the photodiode array and LC/MS/MS data that the colored impurity exists in the drug substance as a pair of double-bond isomers with one isomer at majority. These findings were also confirmed by synthesizing the colored impurity through the proposed pathway.

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 9 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1315893 HCAPLUS
DOCUMENT NUMBER: 144:212486
TITLE: Synthesis of a NO-Releasing Prodrug of Rofecoxib
AUTHOR(S): Engelhardt, F. Conrad; Shi, Yao-Jun; Cowden, Cameron J.; Conlon, David A.; Pipik, Brenda; Zhou, George; McNamara, James M.; Dolling, Ulf-H.
CORPORATE SOURCE: Department of Process Research, Merck Company, Rahway, NJ, 07065-0900, USA
SOURCE: Journal of Organic Chemistry (2006), 71(2), 480-491
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 144:212486
GI



I



III

AB A newly developed synthesis of a NO-releasing prodrug of rofecoxib is described. The highly productive process consists of five chemical steps and produces prodrug I in an overall 64% yield from com. available 3-phenyl-2-propyn-1-ol (II). The synthesis is highlighted by the carbometalation reaction of propargyl alc. II to generate the tetrasubstituted olefin core, sulfone acid III. Addnl., two alternate end-game strategies to prepare NO-COXIB I from this intermediate were explored and developed: (1) a convergent synthesis where a bromonitrate side chain is introduced in one step and (2) a two-step sequence that first installs the requisite six-carbon ester side chain followed by chemoselective nitration.

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 10 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:963804 HCAPLUS
DOCUMENT NUMBER: 143:266677

TITLE: Process for making nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors
INVENTOR(S): Shi, Yao-Jun; Engelhardt, F. Conrad; Cowden, Cameron John; Conlon, David A.; Pipik, Brenda
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 16 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2005192346	A1	20050901	US 2005-66676		20050225
PRIORITY APPLN. INFO.:			US 2004-549126P	P	20040301

OTHER SOURCE(S): CASREACT 143:266677; MARPAT 143:266677
GI



I

AB The invention encompasses a novel process for making prodrugs of cyclooxygenase-2 selective inhibitors that convert in vivo to diaryl-2-(5H)-furanones and also liberate nitric oxide in vivo. As such, the compds. may be co-dosed with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions, effectively reduce the risk of thrombotic cardiovascular events and potentially renal side effects and at the same time reduce the risk of GI ulceration or bleeding. I was prepared starting from 3-phenyl-2-propyn-1-ol and 4-thioanisole magnesium chloride, acetylation, and the intermediate converted to the carboxylic acid, the thio group oxidized to the methylsulfonyl derivative and reaction with 6-bromohexyl nitrate to give I.

L13 ANSWER 11 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:696865 HCAPLUS
DOCUMENT NUMBER: 143:193802
TITLE: Preparation of nitric oxide releasing prodrugs of diaryl-2(5H)-furanones as cyclooxygenase-2 inhibitors
INVENTOR(S): Berthelette, Carl; Li, Lianhai; Beaulieu, Christian; Wang, Zhaoyin; Sturino, Claudio F.
PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Can.
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005070874	A1	20050804	WO 2005-CA84		20050125
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2005206229	A1	20050804	AU 2005-206229		20050125
CA 2554333	A1	20050804	CA 2005-2554333		20050125
EP 1711457	A1	20061018	EP 2005-706414		20050125
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS					
CN 1914151	A	20070214	CN 2005-80003240		20050125
JP 2007520484	T	20070726	JP 2006-549815		20050125
IN 2006DN04343	A	20070713	IN 2006-DN4343		20060727
PRIORITY APPLN. INFO.:			US 2004-540101P	P	20040127
			WO 2005-CA84	W	20050125

OTHER SOURCE(S): CASREACT 143:193802; MARPAT 143:193802
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [n = 1-6; R1 = SO2CH3, SO2NH2; R2-3 = H, halo, alkoxy, etc.; R4 = alkyl, Ph, etc.] are prepared For instance, II is prepared in several steps from 4-(4-(methanesulfonyl)phenyl)-3-phenyl-5H-furan-2-one and hex-5-en-1-ol. I are nitric oxide-releasing prodrugs of diaryl-2(5H)-furanones useful in the treatment of cyclooxygenase-2 mediated diseases [no data]. I may also be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while also reducing the risk of thrombotic cardiovascular events.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 12 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:673257 HCAPLUS
DOCUMENT NUMBER: 143:153219
TITLE: Preparation of prostaglandin nitrooxy derivatives for the treatment of glaucoma
INVENTOR(S): Ongini, Ennio; Benedini, Francesca; Chiroli, Valerio; Del Soldato, Piero
PATENT ASSIGNEE(S): Nicox, S. A., Fr.

SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005068421	A1	20050728	WO 2004-EP14820	20041227
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004313688	A1	20050728	AU 2004-313688	20041227
CA 2551409	A1	20050728	CA 2004-2551409	20041227
EP 1704141	A1	20060927	EP 2004-804405	20041227
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1906159	A	20070131	CN 2004-80039805	20041227
BR 2004018245	A	20070417	BR 2004-18245	20041227
JP 2007518716	T	20070712	JP 2006-546105	20041227
US 2005272743	A1	20051208	US 2005-29698	20050105
IN 2006DN03240	A	20070824	IN 2006-DN3240	20060606
MX 2006PA07678	A	20060901	MX 2006-PA7678	20060704
NO 2006003567	A	20060907	NO 2006-3567	20060807
PRIORITY APPLN. INFO.:			EP 2004-100001 A	20040105
			WO 2004-EP14820 W	20041227

OTHER SOURCE(S): MARPAT 143:153219
GI



I



II

AB Prostaglandin nitrooxy derivs. of formula I [L = benzyl, 3-(trifluoromethyl)phenoxy, 3-chlorophenoxy, (CH2)5Me; X = O, S, NH; Y = alkylene, cycloalkylene, phenylene, etc.] are prepared which have improved pharmacol. activity and enhanced tolerability. They can be employed for the treatment of glaucoma and ocular hypertension. Thus, II was prepared from 4-bromobutyl nitrate (preparation given) and latanoprost acid. The EC50 of II was 2.4 μM for cGMP formation in rat pheochromocytoma cells. Ophthalmic compns. containing I are described.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 13 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:588522 HCAPLUS
DOCUMENT NUMBER: 143:120530
TITLE: Nitric oxide-releasing pyruvate compounds, compositions and methods for treating cardiovascular and other diseases
INVENTOR(S): Garvey, David S.; Fang, Xinqin; Subhash, Khanapure P.; Ramani, Ranatunga R.; Shiow-Jyi, Wey
PATENT ASSIGNEE(S): Nitromed, Inc., USA
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005060603	A2	20050707	WO 2004-US41069	20041210
WO 2005060603	A3	20051201		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004305016	A1	20050707	AU 2004-305016	20041210
CA 2549412	A1	20050707	CA 2004-2549412	20041210
EP 1692107	A2	20060823	EP 2004-813393	20041210
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				

PRIORITY APPLN. INFO.: US 2003-528184P P 20031210
WO 2004-US41069 W 20041210

OTHER SOURCE(S): MARPAT 143:120530

AB The invention describes novel pyruvate compds. comprising at least one nitric oxide-releasing group and pharmaceutically acceptable salts thereof, and compns. and kits comprising at least one of these pyruvate compds., and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The therapeutic agent is, e.g., an aldosterone antagonist, α-adrenoceptor antagonist, an angiotensin II antagonist,

an ACE inhibitor, an antidiabetic, an antihyperlipidemic agent, an antioxidant, an antithrombotic, a vasodilator, a β-adrenoceptor antagonist, a calcium channel blocker, a digitalis, a diuretic, etc. The invention also provides methods for treating cardiovascular diseases, renovascular diseases, diabetes, diseases resulting from oxidative stress, endothelial dysfunctions, diseases caused by endothelial dysfunctions, cirrhosis, pre-eclampsia, osteoporosis, nephropathy, reperfusing injury following ischemia, and/or preserving tissues, organs, organ parts and/or limbs using these compns. The nitric oxide releasing group is preferably a nitro group, a nitroso group, and/or a heterocyclic nitric oxide donor group. The heterocyclic nitric oxide donor group is preferably a furoxan, a sydnonimine, an oxatriazole-5-one and/or an oxatriazole-5-imine. Thus, a mixture of nitrooxy-4-piperidinyl nitrate (1.045 g, 5 mmol) and pyruvic acid (440 mg, 5 mmol) in dichloromethane was treated with triethylamine (0.7 mL). To this solution was added 1-ethyl-3-(3-dimethylaminopropyl)carbamide hydrochloride (EDAC) (960 mg, 5 mmol) followed by dimethylaminopyridine (DMAP, 610 mg, 5 mmol). The resulting solution was then stirred under nitrogen atmospheric at room temperature overnight. The reaction mixture was diluted with dichloromethane and washed with water, brine, dried over sodium sulfate, filtered, and the solvent was evaporated at reduced pressure. The product was purified by column chromatog. to give 1-[4-(nitrooxy)piperidyl]propane-1,2-dione (470 mg, 44% yield) as a colorless thick oil.

L13 ANSWER 14 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:547257 HCAPLUS
DOCUMENT NUMBER: 143:77866
TITLE: Preparation of nitrate esters having a β- or γ-sulfur atom for protection of cells/tissues from oxidative damage.
INVENTOR(S): Thatcher, Gregory R. j.; Bennett, Brian M.; Reynolds, James N.; Boegman, Roland J.; Jhamandas, Khem
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 83 pp., Cont.-in-part of U.S. Ser. No. 147,808.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005137191	A1	20050623	US 2004-943264	20040917
US 5807847	A	19980915	US 1996-658145	19960604
US 5883122	A	19990316	US 1997-867856	19970603
US 6310052	B1	20011030	US 1999-267379	19990315
US 7115661	B1	20061003	US 1999-473713	19991229
EP 1518553	A2	20050330	EP 2004-28372	20001227
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
US 2002177622	A1	20021128	US 2002-147808	20020520
US 6916835	B2	20050712		
AU 2005284573	A1	20060323	AU 2005-284573	20050916
CA 2580627	A1	20060323	CA 2005-2580627	20050916
WO 2006029532	A1	20060323	WO 2005-CA1417	20050916

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EP 1797100 A1 20070620 EP 2005-787832 20050916
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

PRIORITY APPLN. INFO.:

US 1996-658145	A2	19960604
US 1997-867856	A2	19970603
US 1999-267379	A3	19990315
US 1999-473713	A2	19991229
US 2002-147808	A2	20020520
EP 2000-986925	A3	20001227
US 2001-851591	A3	20010510
US 2002-108513	A3	20020329
US 2004-943264	A	20040917
WO 2005-CA1417	W	20050916

OTHER SOURCE(S): MARPAT 143:77866

AB YXCR3R4(CR17R18)n(CR1R2)mONO2 [m, n = 0-10; R3, R4, R17 = H, nitrate, A; R1 = H, A; A = (substituted) (unsatd.) (cyclic) aliphatyl; R1R3, R4R17 = aliphatyl linkage; R2, R18 = H, A, XY; X = F, Cl, Br, Cl, NO2, CH2, CF2, O, NH, NMe, cyano, NHOH, N3, S, SCN, SO, SO2, etc.; Y = null, F, Cl, Br, Cl, Me, CF2H, CF3, OH, NH2, S, SCN, SH, etc.; with provisos], were prepared Thus, [O2NOCH2CH(ONO2)CH2S]2 (prepared via the corresponding Bunte salt) at 200 μmol/kg s.c. gave virtually complete protection against 6-OHDA killing of dopaminergic neurons in rats.

L13 ANSWER 15 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:300267 HCAPLUS
DOCUMENT NUMBER: 142:349032
TITLE: Nitrosylated analgesic and/or antiinflammatory drugs having antiviral activity
INVENTOR(S): Bolla, Manlio; Santus, Giancarlo; De Soldato, Piero
PATENT ASSIGNEE(S): Nicox S.A., Fr.
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030224	A1	20050407	WO 2004-EP51551	20040720

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: EP 2003-292378 A 20030926
OTHER SOURCE(S): MARPAT 142:349032

AB The invention discloses the use of nitrosylated analgesic and/or antiinflammatory drugs for the prevention and/or treatment of viral diseases and/or their complications.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 16 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:300196 HCAPLUS
DOCUMENT NUMBER: 142:355575
TITLE: Preparation of nitrosated glutamic acid compounds for use in pharmaceutical compositions
INVENTOR(S): Garvey, David S.; Earl, Richard A.; Ezawa, Maiko; Fang, Xinqin; Gaston, Ricky D.; Khanapure, Subhash P.; Lin, Chia-en; Ranatunge, Ramani R.; Stevenson, Cheri A.; Wey, Shiow-jyi
PATENT ASSIGNEE(S): Nitromed, Inc., USA
SOURCE: PCT Int. Appl., 151 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030135	A2	20050407	WO 2004-US31372	20040927
WO 2005030135	A3	20050616		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004275809	A1	20050407	AU 2004-275809	20040927
CA 2539973	A1	20050407	CA 2004-2539973	20040927
EP 1673384	A2	20060628	EP 2004-784974	20040927
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007518697	T	20070712	JP 2006-528208	20040927
US 2007037821	A1	20070215	US 2006-573030	20060322
PRIORITY APPLN. INFO.:			US 2003-505921P	P 20030926
			WO 2004-US31372	W 20040927

OTHER SOURCE(S): CASREACT 142:355575; MARPAT 142:355575
GI



I

AB The invention describes novel nitrosated glutamic acid compds. RbNHCH(CH2CH2CO-K)CO-U3-D [Rb is H or alkyl; D is H, V3 or K (V3 is H or NO2); U3 is O, S(O)0-2 or NRaRi, where Ra is a lone pair of electrons, H or alkyl and Ri is H, alkyl, aryl, a carboxylic acid or ester, alkylsulfinyl, etc.; K is -W3a-Eb-(CReRf)p1-Ec-(CReRf)x-W3d-(CReRf)y-W3i-Ej-W3g-(CReRf)z-T3-V3, where a, b, c, d, g, i and j are independently integers 0-3; p1, x, y and z are independently integers 0-10; W3 is CO, CS, T3, (CReRf)1-10, alkyl, aryl, heterocyclyl, arylheterocyclyl or (CH2CH2O)0-5; E is T3, alkyl, aryl, (CReRf)1-10, heterocyclyl, arylheterocyclyl or (CH2CH2O)1-5; T3 is a covalent bond, CO, O, S, SO, SO2 or NRaRi; Re, Rf are independently H, alkyl, cycloalkoxy, halo, hydroxy, hydroxyalkyl, alkoxyalkyl, arylheterocyclyl, alkylaryl, etc.] and their pharmaceutically-acceptable salts and novel compns. comprising at least one nitrosated glutamic acid compound and optionally at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating various diseases and for targeted delivery of compds. and nitric oxide to organs, cells or tissues containing the enzyme γ-glutamyl transpeptidase. Thus, nitrosated glutamic acid ester I.HCl was prepared by esterification of Boc-L-Glu-OBu-t (Boc = tert-butoxycarbonyl) with isosorbide-5-mononitrate (DMAP/EDAC in CH2Cl2) and deprotection.

L13 ANSWER 17 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:120707 HCAPLUS
DOCUMENT NUMBER: 142:191264
TITLE: Preparation of nitro derivatives of heterocyclic compounds as angiotensin II receptor blockers for therapeutic use
INVENTOR(S): Almirante, Nicoletta; Del Soldato, Piero; Ongini, Ennio
PATENT ASSIGNEE(S): Nicox S.A., Fr.
SOURCE: PCT Int. Appl., 104 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005011646	A2	20050210	WO 2004-EP51550	20040720
WO 2005011646	A3	20050421		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004260830	A1	20050210	AU 2004-260830	20040720
CA 2534451	A1	20050210	CA 2004-2534451	20040720
EP 1653950	A2	20060510	EP 2004-766269	20040720
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
CN 1832742	A	20060913	CN 2004-80022483	20040720
BR 2004013028	A	20061003	BR 2004-13028	20040720
JP 2007500684	T	20070118	JP 2006-521571	20040720
AU 2005263655	A1	20060126	AU 2005-263655	20050202
CA 2574666	A1	20060126	CA 2005-2574666	20050202
WO 2006008196	A1	20060126	WO 2005-EP50459	20050202

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EP 1778617	A1	20070502	EP 2005-707928	20050202
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 1984871	A	20070620	CN 2005-80024051	20050202
US 2006276523	A1	20061207	US 2006-566292	20060127
MX 2006PA01263	A	20060411	MX 2006-PA1263	20060131
IN 2006CN00674	A	20070608	IN 2006-CN674	20060223
NO 2006000900	A	20060224	NO 2006-900	20060224
IN 2007CN00727	A	20070824	IN 2007-CN727	20070220

PRIORITY APPLN. INFO.:	EP 2003-102379	A	20030731
	WO 2004-EP51550	W	20040720
	WO 2005-EP50459	W	20050202

OTHER SOURCE(S): CASREACT 142:191264; MARPAT 142:191264

AB Angiotensin II receptor blocker nitro derivs. of formula (I): R-(Y-ONO2)s (I) having wider pharmacol. activity and enhanced tolerability are claimed. They can be employed for treating cardiovascular, renal and chronic liver diseases and inflammatory processes.

L13 ANSWER 18 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:1154582 HCAPLUS
DOCUMENT NUMBER: 142:100367
TITLE: Pharmaceutical compositions based on diclofenac derivative
INVENTOR(S): Gustafsson, Christina; Kjellberg, Ulf; Morein, Sven

PATENT ASSIGNEE(S): Nicox S.A., Fr.
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004112753	A1	20041229	WO 2004-SE1017	20040623
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2529963	A1	20041229	CA 2004-2529963	20040623
EP 1635790	A1	20060322	EP 2004-749055	20040623
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007521267	T	20070802	JP 2006-517054	20040623
US 2006141044	A1	20060629	US 2005-560824	20051215
PRIORITY APPLN. INFO.:			SE 2003-1880 A	20030625
			WO 2004-SE1017 W	20040623

AB The present invention relates to particles comprising the NO-donating diclofenac derivative, 2-[2-(nitrooxy)ethoxy]ethyl {2-[(2,6-dichlorophenyl)amino]phenyl}acetate (I), optionally mixed with one or more surfactant(s) and to a new drug delivery composition comprising said particles optionally in combination with a second drug. Furthermore, the invention relates to processes for preparing said particles and drug delivery composition as well as the use of said composition in the manufacturing of a medicament. For example, 10.5 g I and 29.5 g Pearlitol 100 SD were mixed and the mixture was heated to 75° until the drug was fully melted. The mixture was cooled to room temperature and the powder obtained was sieved through a 0.355 mm sieve. The sieved powder (37.8 g) was mixed with 0.62 g microcryst. cellulose, 0.63 g Polyvidon XL, and 0.41 g Polyvidon K-30, and the powder was wet-granulated. The granulate was dried overnight at 45°, 0.38 g collodial silica was added and the powder was mixed. Sodium stearyl fumarate (0.20 g) was added to the mixture followed by mixing. The granulate was filled into hard gelatin capsules. The drug release from capsules was 12.1%, 33.4%, 60.7%, 79.6% and 88.14% in 5, 10, 20, 45, and 90 min, resp.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 19 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:1124626 HCAPLUS
DOCUMENT NUMBER: 142:79913
TITLE: Enalapril-nitroxy derivatives and related compounds as

ace inhibitors for the treatment of cardiovascular diseases
INVENTOR(S): Almirante, Nicoletta; Ongini, Ennio; Del Soldato, Piero
PATENT ASSIGNEE(S): Nicox S. A., Fr.
SOURCE: PCT Int. Appl., 132 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004110432	A1	20041223	WO 2004-EP51089	20040611
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004246821	A1	20041223	AU 2004-246821	20040611
CA 2529478	A1	20041223	CA 2004-2529478	20040611
EP 1635816	A1	20060322	EP 2004-741779	20040611
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004011430	A	20060725	BR 2004-11430	20040611
CN 1809345	A	20060726	CN 2004-80017127	20040611
US 2005004100	A1	20050106	US 2004-869038	20040617
US 7217733	B2	20070515		
MX 2005PA13771	A	20060308	MX 2005-PA13771	20051215
IN 2006CN00220	A	20070427	IN 2006-CN220	20060117
NO 2006000268	A	20060315	NO 2006-268	20060118

PRIORITY APPLN. INFO.: EP 2003-101796 A 20030619
WO 2004-EP51089 W 20040611

OTHER SOURCE(S): MARPAT 142:79913

AB Disclosure is compds. with a general formula of A-(X1-ONO2)S, wherein A is a known ACE-inhibitor such as enalapril and X1 is a spacer such as a (C1-C6)-alkylene. The compds. can be used as ACE-inhibitors for the treatment of cardiovascular and renal diseases and inflammatory processes. The compds. have an improved pharmacol. activity when compared with the structurally closest related prior art compound For example, synthesized N-[(1S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-L-proline 3-nitrooxypropyl ester hydrogen maleate was found to have good vasorelaxation property.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 20 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:1059168 HCAPLUS
DOCUMENT NUMBER: 142:38061
TITLE: Preparation of nitrooxy derivatives of fluvastatin,

pravastatin, cerivastatin, atorvastatin and rosuvastatin as cholesterol-reducing agents with improved anti-inflammatory, antithrombotic and anti-platelet activity

INVENTOR(S): Benedini, Francesca; Ongini, Ennio; Del Soldato, Piero
PATENT ASSIGNEE(S): Nicox S. A., Fr.
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004105754	A1	20041209	WO 2004-EP50897	20040524
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005165084	A1	20050728	US 2004-849561	20040520
US 7166638	B2	20070123		
AU 2004243443	A1	20041209	AU 2004-243443	20040524
CA 2527168	A1	20041209	CA 2004-2527168	20040524
EP 1626716	A1	20060222	EP 2004-741636	20040524
EP 1626716	B1	20070207		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004010049	A	20060425	BR 2004-10049	20040524
CN 1794987	A	20060628	CN 2004-80014498	20040524
AT 353214	T	20070215	AT 2004-741636	20040524
MX 2005PA12755	A	20060213	MX 2005-PA12755	20051125
NO 2005006152	A	20051223	NO 2005-6152	20051223
IN 2005CN03560	A	20070525	IN 2005-CN3560	20051227
US 2007072942	A1	20070329	US 2006-590770	20061101

PRIORITY APPLN. INFO.:

EP 2003-101530	A	20030527
US 2004-849561	A3	20040520
WO 2004-EP50897	W	20040524

OTHER SOURCE(S): MARPAT 142:38061
GI



I

AB Nitrooxy derivs. of therapeutic agents, such as RCO-X-Y-ONO2 [RCO = acyl residue of therapeutic agents, including statin acids, such as fluvastatin, pravastatin, cerivastatin, atorvastatin and rosuvastatin, ACE inhibitors, angiotensin II receptor antagonists, β-adrenergic blockers, calcium channel blockers, antithrombotics and aspirin; X = O, S, NR1; Y = linking group, such as, alkylene or phenylene alone or in combination; R1 = H, alkyl], with improved pharmacol. activity and enhanced tolerability were prepared for therapeutic use in treating and/or preventing several diseases, in particular coronary syndromes and neurodegenerative disorders and autoimmune disorders , as well as for reducing cholesterol levels. The vascular disorders for treatment include acute coronary syndromes, stroke, peripheral vascular diseases, disorders associated with endothelial dysfunction, peripheral ischemia, vascular complications in diabetic patients and atherosclerosis. The neurodegenerative diseases for treatment include Alzheimer's disease, Parkinson's disease and multiple sclerosis. Thus, ester I was prepared via an esterification reaction of pravastatin sodium with 1,4-dibromobutane n DMF and subsequent treatment of the resulting 4-bromobutanyl pravastatin ester with silver nitrate in MeCN. The prepared nitrooxy statin derivs. were assayed for their ability to induce vasorelaxation, for their effect in vitro on inflammatory pathways, for activity on peripheral vascular disease, for effect on leukocyte adhesion, for antithrombotic activity, for anti-platelet activity, and for inhibition of tissue factor expression.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 21 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:739958 HCAPLUS
DOCUMENT NUMBER: 141:260542
TITLE: Preparation of nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as selective cyclooxygenase-2 inhibitors
INVENTOR(S): Berthelette, Carl; Li, Lianhai; Sturino, Claudio; Wang, Zhaoyin
PATENT ASSIGNEE(S): Merck Frosst Company, Can.
SOURCE: U.S. Pat. Appl. Publ., 19 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004176331	A1	20040909	US 2004-790288	20040301
US 7169809	B2	20070130		
AU 2004240700	A1	20041202	AU 2004-240700	20040301
CA 2517490	A1	20041202	CA 2004-2517490	20040301
WO 2004103955	A1	20041202	WO 2004-CA314	20040301
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1601644	A1	20051207	EP 2004-761562	20040301
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
JP 2007516954	T	20070628	JP 2006-529472	20040301
PRIORITY APPLN. INFO.:			US 2003-452124P	P 20030305
			WO 2004-CA314	W 20040301

OTHER SOURCE(S): MARPAT 141:260542
GI



I



II

AB Title compds. I [X = (CH2)n; n = 3-6; R1 = SO2Me, SO2NH2, SO2NHCOCF3,

etc.; R2, R3 = H, halo, alkoxy, etc.; R4 = CO-alkyl, CO(CH2)mNR5R6; m = 1-4; R5, R6 = H, halo-substituted alkyl] and their pharmaceutically acceptable salts were prepared For example, O-alkylation of AgNO3 by bromide II (Z = Br), e.g., prepared from Rofecoxib in 6-steps, afforded nitrooxyhexyl II (Z = -ONO2). In human blood PGE2 inhibition production assays, nitrooxyhexyl II (Z = -ONO2) exhibited an IC50 value of 0.22 μM. Of note, the "unconverted prodrugs" of compds. I are inactive inhibitors of COX-1 and COX-2 activity. Compds. I are claimed useful for the treatment of cyclooxygenase-2 mediated diseases or conditions.

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 22 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:267282 HCAPLUS
DOCUMENT NUMBER: 140:287165
TITLE: Manufacturing process for NO-donating compounds such as NO-donating diclofenac
INVENTOR(S): Andersson, Johan; Belli, Aldo; Cannata, Vincenzo; Hedberg, Martin; Palmgren, Andreas; Schuldei, Sigrid; Stroem, Marika; Villa, Marco
PATENT ASSIGNEE(S): Astrazeneca UK Limited, UK; Astrazeneca AB
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026808	A1	20040401	WO 2003-SE1465	20030918
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2498943	A1	20040401	CA 2003-2498943	20030918
AU 2003265035	A1	20040408	AU 2003-265035	20030918
BR 2003014365	A	20050719	BR 2003-14365	20030918
EP 1558559	A1	20050803	EP 2003-797782	20030918
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1684940	A	20051019	CN 2003-822285	20030918
JP 2006500409	T	20060105	JP 2004-538109	20030918
ZA 2005002224	A	20060222	ZA 2005-2224	20050316
IN 2005CN00408	A	20070330	IN 2005-CN408	20050317
MX 2005PA03050	A	20050527	MX 2005-PA3050	20050318
US 2006122402	A1	20060608	US 2005-527647	20050801
PRIORITY APPLN. INFO.:			SE 2002-2801 A	20020920
			SE 2003-1476 A	20030520
			WO 2003-SE1465 W	20030918

OTHER SOURCE(S): CASREACT 140:287165; MARPAT 140:287165

AB NO-Donating compds. MLnAmCO2XONOp [M = residue of an NSAID, COX-1 inhibitor or COX-2 inhibitor; L = O, S, CO2, (un)substituted CONH, NH, CO, CH2, CH2CO, CH2CONH, CH2CO2; A = (un)substituted alkylene; X = carbon linker; m, n = 0-3; p= 1, 2] are prepared by treating MLnAmCO2H with HOXOH, treating MLnAmCO2XOH with RSO2Cl [R = alkyl, (un)substituted Ph, CH2Ph, halogen, CF3, C4F9], and treating MLnAmCO2XO3SR with nitrate. A substantially crystalline form of 2-[2-(nitrooxy)ethoxy]ethyl {2-[(2,6-dichlorophenyl)amino]phenyl}acetate is reported.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 23 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:41217 HCAPLUS
DOCUMENT NUMBER: 140:111135
TITLE: Preparation of nitrosated nonsteroidal antiinflammatory compounds
INVENTOR(S): Earl, Richard A.; Ezawa, Maiko; Fang, Xinqin; Garvey, David S.; Gaston, Ricky D.; Khanapure, Subhash P.; Letts, Gordon L.; Lin, Chia-En; Ranatunge, Ramani R.; Richardson, Stewart K.; Schroeder, Joseph D.; Stevenson, Cheri A.; Wey, Shiow-Jyi
PATENT ASSIGNEE(S): Nitromed, Inc., USA
SOURCE: PCT Int. Appl., 145 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004648	A2	20040115	WO 2003-US21026	20030703
WO 2004004648	A3	20041028		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2491127	A1	20040115	CA 2003-2491127	20030703
AU 2003247792	A1	20040123	AU 2003-247792	20030703
US 2004024057	A1	20040205	US 2003-612014	20030703
US 7163958	B2	20070116		
EP 1539729	A2	20050615	EP 2003-763193	20030703
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005539089	T	20051222	JP 2004-562619	20030703
US 2005222243	A1	20051006	US 2005-134358	20050523
PRIORITY APPLN. INFO.:			US 2002-393111P P	20020703
			US 2002-397979P P	20020724
			US 2002-418353P P	20021016
			US 2003-449798P P	20030226
			US 2003-456182P P	20030321

US 2003-612014 A3 20030703
WO 2003-US21026 W 20030703

OTHER SOURCE(S): MARPAT 140:111135
GI



II

AB Title compds. RnRmHC-CO-X [Rm = H, alkyl; Rn = 4-((thiophen-2-yl)carbonyl)phenyl, 3-(benzoyl)phenyl, etc.; X = Y-alkyl-aryl, etc.; Y = O, S; I] are prepared For instance, naproxen is coupled to 2,2'-thiodiethanol (CH2Cl2, DMAP, EDCI) and treated with Ac2O/HNO3 at 0° to give II. I are nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) used alone or are combined with one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase. The invention provides methods for treating inflammation, pain, fever, gastrointestinal disorders, etc.

L13 ANSWER 24 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:2666 HCAPLUS
DOCUMENT NUMBER: 140:65191
TITLE: Oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability
INVENTOR(S): Del Soldato, Piero; Santus, Giancarlo; Macelloni, Cristina
PATENT ASSIGNEE(S): Nicox S.A., Fr.
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000273	A1	20031231	WO 2003-EP6496	20030620
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IT 2002MI1392	A1	20031229	IT 2002-MI1392	20020625

CA 2491152	A1	20031231	CA 2003-2491152	20030620
AU 2003246564	A1	20040106	AU 2003-246564	20030620
EP 1526839	A1	20050504	EP 2003-760660	20030620
EP 1526839	B1	20070314		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1665486	A	20050907	CN 2003-815181	20030620
JP 2005530835	T	20051013	JP 2004-514802	20030620
NZ 537204	A	20060728	NZ 2003-537204	20030620
AT 356612	T	20070415	AT 2003-760660	20030620
ZA 2004010109	A	20050902	ZA 2004-10109	20041214
MX 2004PA12852	A	20050608	MX 2004-PA12852	20041216
NO 2005000347	A	20050121	NO 2005-347	20050121
US 2006171969	A1	20060803	US 2005-515621	20050912
PRIORITY APPLN. INFO.:			IT 2002-MI1392 A	20020625
			WO 2003-EP6496 W	20030620

GI



I

AB The present invention relates to new pharmaceutical compns. for the administration of liquid drugs in solid oral forms, said compns. comprising one or more active ingredients, one or more surface-active agents and optionally a co-surfactant and/or an absorption enhancer absorbed on a solid inert carrier. An emulsion was prepared containing I 100, Cremophor EL 50, Phospholipon 80H 50, Aerosil 200 100, and Explotab 100 g.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 25 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:991299 HCAPLUS
DOCUMENT NUMBER: 140:35983
TITLE: Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
INVENTOR(S): Letts, L. Gordon; Garvey, David S.
PATENT ASSIGNEE(S): Nitromed, Inc., USA
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2003103602	A2	20031218	WO 2003-US18052		20030610
WO 2003103602	A3	20040401			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2487414	A1	20031218	CA 2003-2487414		20030610
AU 2003248642	A1	20031222	AU 2003-248642		20030610
US 2004072899	A1	20040415	US 2003-718060		20030610
US 7220749	B2	20070522			
EP 1539134	A2	20050615	EP 2003-757428		20030610
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2006501161	T	20060112	JP 2004-510723		20030610
US 2007179195	A1	20070802	US 2007-730886		20070404
PRIORITY APPLN. INFO.:			US 2002-387433P	P	20020611
			US 2003-718060	A3	20030610
			WO 2003-US18052	W	20030610

OTHER SOURCE(S): MARPAT 140:35983

AB The invention describes novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) selective inhibitors and novel compns. comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or, optionally, at least one therapeutic agent. The invention also provides novel compns. comprising at least one COX-2 selective inhibitor, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors. The invention also provides novel kits comprising at least one COX-2 selective inhibitor optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention are preferably 2(2-((2-chloro-6-fluorophenyl) amino)5-methylphenyl)acetic acid and nitrosated derivs. thereof.

L13 ANSWER 26 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:818296 HCAPLUS
DOCUMENT NUMBER: 139:302040
TITLE: Nitrooxy derivatives of antiinflammatory/analgesic compounds for the treatment of arthritis
INVENTOR(S): Del Soldato, Piero
PATENT ASSIGNEE(S): Nicox S.A., Fr.
SOURCE: PCT Int. Appl., 71 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003084550	A1	20031016	WO 2003-EP3183	20030327
W: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GE, HR, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, SG, TN, TT, UA, US, UZ, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IT 2002MI0773	A1	20031013	IT 2002-MI773	20020411
AU 2003224002	A1	20031020	AU 2003-224002	20030327
EP 1492543	A1	20050105	EP 2003-720377	20030327
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005522472	T	20050728	JP 2003-581790	20030327
US 2007010458	A1	20070111	US 2006-509675	20060913
PRIORITY APPLN. INFO.:			IT 2002-MI773 A	20020411
			WO 2003-EP3183 W	20030327

OTHER SOURCE(S): MARPAT 139:302040

AB Antiinflammatory and/or antiinflammatory/analgesic compds. having the formula A(B)b0(C)c0-N(O)s [A contains radical of nonsteroidal antiinflammatory or nonsteroidal antiinflammatory/analgesic drug; B, C = bivalent linking group; s = 1, 2; b0, c0 = 0, 1 (with proviso)], and salts thereof, are disclosed for use in the treatment of arthritis.

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 27 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:777566 HCAPLUS
DOCUMENT NUMBER: 139:281272
TITLE: Nitric oxide-donating NSAIDS adsorbed into carrier particles
INVENTOR(S): Morein, Sven; Berg, Mats; Holmberg, Christina; Lundberg, Per Johan; Anders, Ringberg
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca Uk Limited
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003080029	A1	20031002	WO 2003-SE468	20030320
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,				

PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003216006	A1	20031008	AU 2003-216006	20030320
EP 1490033	A1	20041229	EP 2003-745055	20030320
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005129774	A1	20050616	US 2003-507368	20030320
JP 2005533751	T	20051110	JP 2003-577859	20030320
PRIORITY APPLN. INFO.:			SE 2002-895 A	20020322
			WO 2003-SE468 W	20030320

AB The present invention relates to porous particles comprising NO-donating nonsteroidal anti-inflammatory compound optionally mixed with surfactants and to new solid drug delivery composition comprising the particles optionally in combination with a second active drug. Furthermore, the invention relates to processes for producing the porous particles and solid drug delivery composition as well as the use of the composition in the manufacture of a medicament. The NO-donating NSAID may be in an oily or melted form. Thus, a tablet comprised 4-(nitrooxy)butyl (S)-2-(9-methoxy-2-naphthyl)propanoate (I) 250 and omeprazole 20 mg. Enteric over-coated pellets comprised omeprazole and a powder of the porous particles containing I were manufactured sep. before compressing the 2 components.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 28 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:652131 HCAPLUS
DOCUMENT NUMBER: 139:214237
TITLE: Preparation of nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
INVENTOR(S): Scaramuzzino, Giovanni
PATENT ASSIGNEE(S): Italy
SOURCE: Eur. Pat. Appl., 313 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1336602	A1	20030820	EP 2002-425075	20020213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			EP 2002-425075	20020213

GI



II

AB New pharmaceutical compds. of general formula F-(X)q (I) [q = 1-5, preferably 1; F is chosen among drugs such as δ-tocopherol, clidanac, diethylhomospermine, glucosamine, thymocartin, vofopitant, etc.; X is chosen among 4 groups M, T, V, and Y where M = ONO2, nitrate salt, nitrite ester, ONO, thoinitrite, SNO, etc., T = OR1-M, OR1OR1-M, SR1NR2R1-M, NR2R1-M, NR2R1SR1-M, etc., R1 = saturated or unsatd., linear or branched alkylene, having 1 to 21 carbon atoms or a saturated or unsatd., optionally heterosubstituted or branched cycloalkylene, having 3 to 7 carbon atoms or an optionally heterosubstituted arylene having 3 to 7 carbon atoms; R2 = H, saturated or unsatd., linear or branched 1-21 carbon atom alkyl, saturated or unsatd. optionally heterosubstituted or branched 3-7 carbon cycloalkyl, optionally heterosubstituted 3-7 carbon aryl; R1, R2 = OH, SH, F, Cl, Br, OPO3H2, CO2H, etc.; bond between F and T = carboxylic ester, carboxylic amide, glycoside, azo, thioester, sulfonic ester, etc.; V = Z-M2, OZ-M2, NR2Z-M2, R1Z-M2, OR1-M2, OR1Z-M2, M2 = M, R1-M, OR1-M, SR1-M, NR2R1-M; ZM2 = COCH2CH(M2)CH2N+Me3, COCH2CH2COM2, COCH(NHR2)CH2M2, etc.; Y = 4-COC6H4CH2ONO2, O(CH2)4ONO2, COCH(NH2)CH2ONO2, 3-OC6H4CH2ONO2, etc.] were prepared For example, α-tocopherol reacted with 4-HO2CC6H4CH2ONO2 to give the nitroxymethyl derivative II. The compds. of general formula I are nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without hypotensive side effects and for this reason they are useful for the preparation of medicines for prevention and treatment of inflammatory, ischemic, degenerative and proliferative diseases of musculoskeletal, tegumental, respiratory, gastrointestinal, genito-urinary and central nervous systems.

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 29 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:364668 HCAPLUS
DOCUMENT NUMBER: 139:127237
TITLE: Nitric oxide-donating non-steroidal anti-inflammatory drugs: the case of nitro derivatives of aspirin
AUTHOR(S): Chiroli, Valerio; Benedini, Francesca; Ongini, Ennio; Del Soldato, Piero
CORPORATE SOURCE: Nicox Research Institute, Bresso, Milan, 20091, Italy
SOURCE: European Journal of Medicinal Chemistry (2003), 38(4), 441-446
CODEN: EJMCA5; ISSN: 0223-5234
PUBLISHER: Editions Scientifiques et Medicales Elsevier
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. Nitric oxide (NO) acts as a key signaling mechanism in a number of cells and tissues in the mammalian organism. Modulation of the

biosynthesis of NO has emerged to be relevant to the treatment of a variety of human diseases. In the attempt to reduce the serious side effects of non-steroidal anti-inflammatory drugs (NSAIDs), especially in the gastrointestinal tract, a NO-releasing moiety has been linked to conventional NSAIDs. A prototypical example is that of NO-releasing derivs. of aspirin. Thanks to the cytoprotective action of NO such compds. do not produce gastric damage and are emerging as an interesting novel group of drugs for their unique pharmacol. properties.

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 30 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:221490 HCAPLUS
DOCUMENT NUMBER: 138:260440
TITLE: Self emulsifying drug delivery system containing NSAIDs
INVENTOR(S): Holmberg, Christina
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022249	A1	20030320	WO 2002-SE1598	20020905
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002329149	A1	20030324	AU 2002-329149	20020905
EP 1427392	A1	20040616	EP 2002-765747	20020905
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005504788	T	20050217	JP 2003-526379	20020905
US 2004248974	A1	20041209	US 2004-488585	20040304
PRIORITY APPLN. INFO.:			SE 2001-2993 A	20010907
			WO 2002-SE1598 W	20020905

OTHER SOURCE(S): MARPAT 138:260440

AB A pharmaceutical composition suitable for oral administration, in form of an emulsion pre-concentrate, comprises 1 or more NO-releasing NSAID(s), 1 or more surfactants, of which at least one is phospholipid, the composition forming an in-situ oil-in-water emulsion upon contact with gastrointestinal fluids. The composition may optionally also comprise an addnl. oil or semi-solid fat. Further, 1 or more short-chain alcs. can optionally be included in the composition Also within the scope of the invention is a combination with a proton pump inhibitor. The pharmaceutical composition is useful in the treatment of pain and inflammation. Further within the scope of the invention is kit comprising a pharmaceutical composition according to the

invention in a unit dosage form, in combination with a proton pump inhibitor, and the proton pump inhibitor is enteric coated. Thus, a formulation contained Lipoid S100 0.30, propylene glycol 0.90, and a NO-releasing NSAID 4.00 g.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 31 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:736089 HCAPLUS
DOCUMENT NUMBER: 137:253012
TITLE: Pharmaceutical compositions containing NO-releasing NSAID and surfactants
INVENTOR(S): Siekmann, Britta; Thoring, Barbro
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002074282	A1	20020926	WO 2002-SE476	20020313
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2435825	A1	20020926	CA 2002-2435825	20020313
AU 2002237630	A1	20021003	AU 2002-237630	20020313
EP 1370239	A1	20031217	EP 2002-704035	20020313
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1496253	A	20040512	CN 2002-806527	20020313
BR 2002007760	A	20040601	BR 2002-7760	20020313
JP 2004523577	T	20040805	JP 2002-572990	20020313
MX 2003PA07093	A	20031118	MX 2003-PA7093	20030807
ZA 2003006282	A	20041123	ZA 2003-6282	20030813
US 2004096494	A1	20040520	US 2003-471378	20030909
NO 2003004026	A	20031111	NO 2003-4026	20030911
PRIORITY APPLN. INFO.:			SE 2001-901 A	20010315
			WO 2002-SE476 W	20020313

OTHER SOURCE(S): MARPAT 137:253012

AB A new pharmaceutical composition in the form of lipoglobules comprises (a) 1 or more NO-releasing NSAIDs; (b) 1 or more surfactants; and (c) an aqueous phase, and is useful for the treatment of pain and inflammation. Thus, a composition contained 4-(nitrooxy)butyl 6-methoxy-α-methyl-2-naphthaleneacetate 0.77, fractionated coconut oil 2.97, Phospholipon-80 0.76, and Poloxamer-407 1.61 mg/g.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 32 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:676579 HCAPLUS
DOCUMENT NUMBER: 135:231708
TITLE: New self emulsifying drug delivery system
INVENTOR(S): Holmberg, Christina; Siekmann, Britta
PATENT ASSIGNEE(S): AstraZeneca AB, Swed.
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001066088	A1	20010913	WO 2001-SE467	20010306
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2401498	A1	20010913	CA 2001-2401498	20010306
EP 1267832	A1	20030102	EP 2001-910305	20010306
EP 1267832	B1	20040602		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001009014	A	20030603	BR 2001-9014	20010306
JP 2003525894	T	20030902	JP 2001-564741	20010306
HU 200300882	A2	20030929	HU 2003-882	20010306
EE 200200500	A	20040216	EE 2002-500	20010306
AT 268162	T	20040615	AT 2001-910305	20010306
NZ 521009	A	20040625	NZ 2001-521009	20010306
PT 1267832	T	20040930	PT 2001-910305	20010306
ES 2220728	T3	20041216	ES 2001-1910305	20010306
RU 2270675	C2	20060227	RU 2002-122744	20010306
IN 2002MN01102	A	20050304	IN 2002-MN1102	20020816
ZA 2002006740	A	20031124	ZA 2002-6740	20020822
MX 2002PA08657	A	20030224	MX 2002-PA8657	20020904
US 2003161846	A1	20030828	US 2002-220791	20020905
NO 2002004272	A	20021105	NO 2002-4272	20020906
HK 1050632	A1	20050318	HK 2003-102781	20030416

PRIORITY APPLN. INFO.: SE 2000-773 A 20000308
WO 2001-SE467 W 20010306

OTHER SOURCE(S): MARPAT 135:231708

AB The present invention claims and discloses a pharmaceutical composition suitable for oral administration, in form of an emulsion pre-concentrate, comprising: 1 or more NO-releasing NSAID(s), 1 or more surfactants, optionally an addnl. oil or semi-solid fat. The composition forms an in-situ oil-in-water emulsion upon contact with gastrointestinal fluids. The composition may optionally also comprise 1 or more short-chain alcs. Also within the scope of the invention is a combination with a proton pump inhibitor. The pharmaceutical composition is useful in the treatment of pain and inflammation. Further within the scope of the invention is kit

comprising a pharmaceutical composition according to the invention in a unit dosage form, in combination with a proton pump inhibitor, and the proton pump inhibitor is enteric coated. Thus, a semisolid formulation contained a NO-releasing NSAID 750, Pluronic F127 450, and omeprazole 20 g.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 33 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:137173 HCAPLUS
DOCUMENT NUMBER: 134:178396
TITLE: Synthesis, activity and formulations of pharmaceutical compounds for treatment of oxidative stress and/or endothelial dysfunction
INVENTOR(S): Del Soldato, Piero
PATENT ASSIGNEE(S): Nicox S.A., Fr.
SOURCE: PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001012584	A2	20010222	WO 2000-EP7225	20000727
WO 2001012584	A3	20020829		
W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
IT 99MI1817	A1	20010212	IT 1999-MI1817	19990812
CA 2381409	A1	20010222	CA 2000-2381409	20000727
BR 2000013264	A	20020416	BR 2000-13264	20000727
EP 1252133	A2	20021030	EP 2000-953102	20000727
EP 1252133	B1	20050608		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
HU 200203939	A2	20030328	HU 2002-3939	20000727
JP 2003515526	T	20030507	JP 2001-516885	20000727
CN 1433396	A	20030730	CN 2000-814049	20000727
NZ 516889	A	20041029	NZ 2000-516889	20000727
AU 781643	B2	20050602	AU 2000-65670	20000727
AT 297375	T	20050615	AT 2000-953102	20000727
EP 1593664	A1	20051109	EP 2005-104064	20000727
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY				
RU 2264383	C2	20051120	RU 2002-103509	20000727
ES 2243292	T3	20051201	ES 2000-953102	20000727
NZ 535559	A	20051223	NZ 2000-535559	20000727
CN 1923797	A	20070307	CN 2006-10136231	20000727
ZA 2002000628	A	20030423	ZA 2002-628	20020123
US 7186753	B1	20070306	US 2002-48469	20020207
NO 2002000623	A	20020409	NO 2002-623	20020208
MX 2002PA01519	A	20020702	MX 2002-PA1519	20020211

AU 2005202824	A1	20050721	AU 2005-202824	20050628
IN 2006CN01908	A	20070608	IN 2006-CN1908	20060530
US 2007197499	A1	20070823	US 2006-642783	20061221
PRIORITY APPLN. INFO.:			IT 1999-MI1817	A 19990812
			CN 2000-814049	A3 20000727
			EP 2000-953102	A3 20000727
			IN 2002-CN187	A3 20000727
			WO 2000-EP7225	W 20000727
			US 2002-48469	A1 20020207

OTHER SOURCE(S): MARPAT 134:178396

AB Compds. or their salts of general formula (I): A-B-N(O)s wherein: s is an integer equal to 1 or 2; A = R-T1-, wherein R is the drug radical and T1 = (CO)t or (X)t', wherein X = O, S, NR1c, R1c is H or a linear or branched alkyl or a free valence, t and t' are integers and equal to zero or 1, with the proviso that t = 1 when t' = 0; t = 0 when t' = 1; B = -TB -X2-O- wherein TB = (CO) when t = 0, TB = X when t' = 0, X being as above defined; X2, bivalent radical, is such that the precursor drug of A and the precursor of B meet resp. the pharmacol. tests described in the description. Synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction are disclosed. The precursors are such as to meet the pharmacol. test reported in the description.

L13 ANSWER 34 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:861483 HCAPLUS
DOCUMENT NUMBER: 134:25340
TITLE: New use of compounds as antibacterial agents
INVENTOR(S): Eek, Arne; Raud, Johan
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000072838	A1	20001207	WO 2000-SE1071	20000525
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
TW 243672	B	20051121	TW 2000-89109689	20000519
CA 2373653	A1	20001207	CA 2000-2373653	20000525
BR 2000011116	A	20020219	BR 2000-11116	20000525
EP 1196155	A1	20020417	EP 2000-937451	20000525
EP 1196155	B1	20040804		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200103474	T2	20020422	TR 2001-3474	20000525
HU 200201502	A2	20020828	HU 2002-1502	20000525

JP 2003500442	T	20030107	JP 2000-620950		20000525
EE 200100647	A	20030217	EE 2001-647		20000525
NZ 515317	A	20040528	NZ 2000-515317		20000525
AT 272396	T	20040815	AT 2000-937451		20000525
AU 780678	B2	20050407	AU 2000-52623		20000525
RU 2252032	C2	20050520	RU 2001-135826		20000525
US 6593339	B1	20030715	US 2000-673007		20000929
IN 2001MN01424	A	20050304	IN 2001-MN1424		20011115
ZA 2001009497	A	20030217	ZA 2001-9497		20011116
BG 106158	A	20020628	BG 2001-106158		20011128
MX 2001PA12295	A	20020730	MX 2001-PA12295		20011129
NO 2001005855	A	20020130	NO 2001-5855		20011130
HK 1045814	A1	20050401	HK 2002-107373		20021009
US 2004048917	A1	20040311	US 2003-426952		20030501
PRIORITY APPLN. INFO.:			SE 1999-2027	A	19990601
			SE 1999-4704	A	19991221
			WO 2000-SE1071	W	20000525
			US 2000-673007	A1	20000929

AB The present invention discloses a new use of NO-releasing NSAIDs, especially NO-releasing NSAIDs of formula (I), or a pharmaceutically acceptable salt or enantiomer thereof, for the manufacture of a medicament for the treatment of bacterial infections, especially caused or mediated by Helicobacter pylori. Disclosed is also the new use of a NO-releasing NSAID in combination with an acid susceptible proton pump inhibitor for the treatment of bacterial infections.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 35 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:76862 HCAPLUS
DOCUMENT NUMBER: 130:186296
TITLE: Thermal stability of peroxynitrates
AUTHOR(S): Kirchner, F.; Mayer-Figge, A.; Zabel, F.; Becker, K. H.
CORPORATE SOURCE: Bergische Universitat-Gesamthochschule Wuppertal, Physikalische Chemie/FB 9, Wuppertal, 42097, Germany
SOURCE: International Journal of Chemical Kinetics (1999), 31(2), 127-144
CODEN: IJCKBO; ISSN: 0538-8066
PUBLISHER: John Wiley & Sons, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Peroxynitrates are thermally unstable intermediates (at ambient temps.) in the atmospheric degradation of hydrocarbons. Thermal lifetimes of 9 peroxynitrates were measured as a function of temperature and, for 2 of them, also, as a function of total pressure. In the presence of excess NO, relative concns. of peroxynitrates were followed in a 420 L reaction chamber as a function of time using long-path IR absorption with a Fourier transform spectrometer. Original data on the unimol. decomposition rate consts. are presented for the peroxynitrates RO2NO2 with R = C6H11, CH3C(O)CH2, C6H5CH2, CH2I, CH3C(O)OC(H)CH3, C6H5OCH2, (CH3)2NC(O), C6H5OC(O), and C2H5C(O). Thermal lifetimes at room temperature and atmospheric pressure are very short (on the order of seconds) for substituted Me peroxynitrates (i.e., R'CH2O2NO2) but rather long for substituted formyl peroxynitrates (i.e., R''C(O)O2NO2). Kinetic data from this and previous laboratory work were used to

derive structure-stability relationships allowing an estimate of the thermal lifetimes of peroxynitrates from readily available 13C NMR shift data.

REFERENCE COUNT: 67 THERE ARE 67 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 36 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:681459 HCAPLUS
DOCUMENT NUMBER: 125:328304
TITLE: Preparation of nitric esters of 2-(2,6-dihalophenylamino)phenylacetoxyacetic acid derivatives
INVENTOR(S): Serra, Masia Xavier; Pi Sallent, Joan
PATENT ASSIGNEE(S): Prodes, S.A., Spain
SOURCE: Eur. Pat. Appl., 16 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 738706	A1	19961023	EP 1996-106009	19960417
EP 738706	B1	19981007		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
ES 2092962	A1	19961201	ES 1995-756	19950419
ES 2092962	B1	19970716		
AU 9650428	A	19961031	AU 1996-50428	19960401
AU 683790	B2	19971120		
ZA 9602981	A	19961022	ZA 1996-2981	19960415
CA 2174287	A1	19961020	CA 1996-2174287	19960416
HU 9600996	A2	19961128	HU 1996-996	19960417
CN 1138027	A	19961218	CN 1996-105067	19960417
AT 171936	T	19981015	AT 1996-106009	19960417
NO 9601537	A	19961021	NO 1996-1537	19960418
JP 09020738	A	19970121	JP 1996-98815	19960419
US 5844696	A	19981201	US 1996-634763	19960419
BR 9603235	A	19980428	BR 1996-3235	19960731

PRIORITY APPLN. INFO.: ES 1995-756 A 19950419
OTHER SOURCE(S): CASREACT 125:328304; MARPAT 125:328304
GI



I

AB The title compds. [I; A = F, Cl, Br; X = O, NH, NR (R = C1-8 alkyl); R1, R2 = C1-8 alkyl, n = 1-10], potentially useful as antiinflammatory agents (no data), were prepared by condensation of 2-(2,6-dihalophenylamino)phenylacetoxyacetic acid with a compound Y-(C)nR1R2ONO2 [Y = OH, NH2, NHR] in the presence of condensing agent such as N,N'-carbonyl diimidazole in an aprotic organic solvent.

L13 ANSWER 37 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:163887 HCAPLUS
DOCUMENT NUMBER: 124:201789
TITLE: Preparation of aryl nitrate ester compounds having antiinflammatory ans well as analgesic and antithrombotic activities
INVENTOR(S): Del Soldato, Piero; Sannicolo', Francesco
PATENT ASSIGNEE(S): Nicox Ltd., Ire.
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9530641	A1	19951116	WO 1995-EP1233		19950404
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, UZ, VN					
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
CA 2190087	C	19951116	CA 1995-2190087		19950404
CA 2190087	A1	19951116			
AU 9522156	A	19951129	AU 1995-22156		19950404
AU 702662	B2	19990225			
EP 759899	A1	19970305	EP 1995-915185		19950404
EP 759899	B1	19990915			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE					
HU 75961	A2	19970528	HU 1996-3107		19950404
BR 9507634	A	19970923	BR 1995-7634		19950404
JP 09512798	T	19971222	JP 1995-528615		19950404
AT 184589	T	19991015	AT 1995-915185		19950404
ES 2139199	T3	20000201	ES 1995-915185		19950404
RU 2145595	C1	20000220	RU 1996-123280		19950404
US 5861426	A	19990119	US 1997-737426		19970306
US 5780495	A	19980714	US 1997-902570		19970729
GR 3032078	T3	20000331	GR 1999-403169		19991208
PRIORITY APPLN. INFO.:			IT 1994-MI916	A	19940510
			IT 1994-MI1731	A	19940809
			GB 1993-20599	A	19931006
			WO 1995-EP1233	W	19950404
			US 1996-624508	A3	19960405

OTHER SOURCE(S): MARPAT 124:201789
GI



I

AB The title compds. AX1NO2 [A = R(COXu)t; t = 0, 1; u = 0, 1; X = O, (un)substituted NH or NR1c wherein R1c = alkyl; R = (un)substituted Ph, etc.; X = YO; Y = alkylene, cycloalkylene, oxyalkyl, etc.] (e.g., I), which inhibit cyclooxygenase, are prepared

L13 ANSWER 38 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1994:630196 HCAPLUS
DOCUMENT NUMBER: 121:230196
TITLE: Kinetic studies of peroxynitrates and peroxy radicals
AUTHOR(S): Becker, K. H.; Kirchner, F.
CORPORATE SOURCE: Germany
SOURCE: Ber. - Bergische Univ., Gesamthochsch. Wuppertal, Fachbereich 9, Phys. Chem. (1994), 29, 123 pp.
CODEN: BBWCE4
DOCUMENT TYPE: Report
LANGUAGE: German
AB Rate consts. were determined for the thermal decomposition of peroxynitrates RO2NO2
+ M → RO2 + NO2 + M, where R = Bz, CH3OC(O), C6H5OC(O), (CH3)2NC(O), CCl2FC(O), CClF2C(O), CF3C(O), CCl2FCH2, CClF2CH2, CH3OCH2, C6H5OCH2, AcOCH(CH3), C6H5CH2, CH3C(O)CH2, C6H11, CH2I. Under standard conditions the rate consts. differ by a factor of 60,000 depending on R. All the acyl peroxynitrates are thermally much more stable than any of the alkyl peroxynitrates. From a comparison of the results of this work with other measurements from this laboratory the following conclusions can be drawn: The thermal stability of peroxynitrates is highly dependent on the electron d. at the carbon atom next to the O2NO2 group. Electron withdrawing substituents increase the thermal stability of peroxynitrates compared to substituents which are less electron withdrawing. For alkyl peroxynitrates inductive effects are most important. The electronegativities of the atoms next to the C atom of the CO2NO2 group will therefore determine the thermal stability of RO2NO2. For acyl peroxynitrates mesomeric effects are more important than for alkyl peroxynitrates and cannot be neglected. Correlation of the activation energies of thermal decomposition with 13C-NMR signal shifts δ of the corresponding R-X compds. (X = OCH3, Cl, F, H, OH, CH3) is discussed. Measurements for CH2IO2NO2 suggest that these equations are not valid if the substituents are heavy atoms. The ratios of the rate consts. of the reactions RO2 + NO2 + M → RO2NO2 + M and RO2 + NO → products were measured for three different RO2 radicals.

L13 ANSWER 39 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1983:521838 HCAPLUS
DOCUMENT NUMBER: 99:121838
TITLE: Nitroacetic acid ester
INVENTOR(S): Hamamoto, Toshikazu; Sugise, Ryoji
PATENT ASSIGNEE(S): Ube Industries, Ltd. , Japan
SOURCE: Ger. Offen., 15 pp.
CODEN: GWXXBX

DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3246253	A1	19830630	DE 1982-3246253	19821214
DE 3246253	C2	19901011		
JP 58105944	A	19830624	JP 1981-202545	19811217
JP 03025411	B	19910405		
US 4433162	A	19840221	US 1982-447471	19821206
GB 2111494	A	19830706	GB 1982-34896	19821207
GB 2111494	B	19851023		
FR 2518539	A1	19830624	FR 1982-21249	19821217
FR 2518539	B1	19860321		

PRIORITY APPLN. INFO.: JP 1981-202545 A 19811217
OTHER SOURCE(S): MARPAT 99:121838

AB O2NCH2CO2R (I) (R = alkyl, etc.) were prepared by treatment of a vinyl alkanoate with N2O5, then an alc. Thus, 3.10 g N2O5 and 3.020 mL O were passed over 2 h into 2.70 g CH2:CHOAc in 30 mL EtOAc at 15°, the mixture was stirred 10 min, 8.0 g MeOH were added at 10°, and the mixture was stirred 10 min to give 53% O2NCH2CO2Me. Also prepared were I (R = Pr, Bu, PhCH2, cyclohexyl).

L13 ANSWER 40 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1976:73636 HCAPLUS
DOCUMENT NUMBER: 84:73636
TITLE: Substituted nitroalkyl peroxynitrate
INVENTOR(S): Cummings, William M.
PATENT ASSIGNEE(S): Texaco Inc., USA
SOURCE: U.S., 6 pp. Division of U.S. 3,853,944.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3910987	A	19751007	US 1974-430305	19740102
US 3732283	A	19730508	US 1971-144212	19710517
US 3853944	A	19741210	US 1972-311993	19721204
US 3910981	A	19751007	US 1974-430306	19740102

PRIORITY APPLN. INFO.: US 1971-144212 A 19710517
US 1972-311993 A3 19721204

AB About 12 allyl compds., RCH2CH:CH2 (R = e.g., AcO, BzO, OEt, Ph, Cl, cyano), were treated with N2O4 and O in CCl4 at .apprx.0-5° to give the peroxynitrates, RCH2CH(OONO2)CH2NO2, which (without isolation) were treated with NO at .apprx.-10° to give the nitrates, RCH2CH(ONO2)CH2NO2 (I). I are useful as fuel additives to increase the power output of petroleum distillates such as gasoline and kerosine (no data).

L13 ANSWER 41 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1974:110522 HCAPLUS
DOCUMENT NUMBER: 80:110522

TITLE: Propellants of pulsed combustion
INVENTOR(S): Wasmann, Friedrich W.
PATENT ASSIGNEE(S): Germany, Federal Republic of
SOURCE: Ger. Offen., 9 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2235744	A1	19740131	DE 1972-2235744	19720721
DE 2235744	B2	19750605		
DE 2235744	C3	19760122		
FR 2193799	A1	19740222	FR 1973-26639	19730719

PRIORITY APPLN. INFO.: DE 1972-2235744 A 19720721

AB Propellants with constant pulsed combustion (alternating smoldering and burning) consist of copolymers of polyol nitrate (meth)acrylates with vinyl compds., e.g. glycerol dinitrate acrylate-vinyl acetate copolymer (I), as smoldering components and fuels, resp. Inorg. perchlorates, e.g. LiClO4, are used as oxidizers. Thus, glycerol dinitrate acrylate 20-60, vinyl acetate 20-40, LiClO4 20-40, and Ba2O2 5% are heated 48 hr at 50° in closed glass tubes to give a propellant containing I with combustion pulse sequence 0.2-2 Hz.

L13 ANSWER 42 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1974:61665 HCAPLUS
DOCUMENT NUMBER: 80:61665
TITLE: Solid propellants with pulsatory characteristics
AUTHOR(S): Wasmann, Friedrich W.
CORPORATE SOURCE: Inst. Chem. Treib- Explosivst., Fraunhoferges., Berghausen-Hummelberg, Fed. Rep. Ger.
SOURCE: Explosivstoffe (1973), 21(1), 1-8
CODEN: EXPVA5; ISSN: 0014-5068
DOCUMENT TYPE: Journal
LANGUAGE: German

AB Solid propellants were prepared from copolymers mixed with inorg. O carriers. Unlike the usual solid propellants, these new systems have a burning rate that varies periodically at a frequency of 0.1-1000 Hz. The compns., methods of preparation, and properties of these new propellants are described. Nitrate group-containing monomers include ethylene glycol mononitrate, diglycol mononitrate, glycerol mono- and dinitrate, and pentaerythritol mono-, di-, and trinitrate. Copolymer components include styrene, vinyl acetate, and acrylic and methacrylic acid esters. Inorg. O-containing salts include Li, Ca, Sr, and Ba perchlorate.

L13 ANSWER 43 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1973:42848 HCAPLUS
DOCUMENT NUMBER: 78:42848
TITLE: 1-Nitro-2-nitratopropanes
INVENTOR(S): Cummings, William Michael
PATENT ASSIGNEE(S): Texaco Development Corp.
SOURCE: Ger. Offen., 20 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2157648	A	19721130	DE 1971-2157648	19711120
US 3732283	A	19730508	US 1971-144212	19710517
GB 1319890	A	19730613	GB 1971-54072	19711122
CA 984400	A1	19760224	CA 1972-142022	19720512

PRIORITY APPLN. INFO.: US 1971-144212 A 19710517

AB Thirteen title compds. O2NCH2CR(ONO2)CH2R1 (I; R = H or Me; R1 = OAc, O2CH, O2CCF3, O2CEt, O2CC6H13, Bz, ONO2, Cl, OEt, OPh, Ph, or CN), useful for improving the pour output of gasoline, were prepared via the peroxynitrates O2NCH2CR(OONO2)CH2R1 (II) by reaction of CH2:CRCH2R1 with N2O4 and O. Thus, 1:20 N2O4-O was added to CH2:CHCH2OAc 6 hr at 0° to give II (R = H, R1 = OAc), which on treatment with NO 30 min at -10° gave 90% I (R = H, R1 = OAc).

L13 ANSWER 44 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1957:62090 HCAPLUS
DOCUMENT NUMBER: 51:62090
ORIGINAL REFERENCE NO.: 51:11244b-i
TITLE: Action of nitrogen peroxides on epoxides
AUTHOR(S): Pujo, Anne Marie; Boileau, Jacques
SOURCE: Memorial des Poudres (1955), 37, 35-48
CODEN: MPOUAT; ISSN: 0369-1535
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB Anhydrous N2O4 (I) reacted with ethylene oxide (II) and with propylene oxide (III) to give mixts. of glycol nitrite nitrates. Adding 44 g. II in 250 mL. CHCl3 or Et2O slowly to a solution of 92 g. I in 500 mL. CHCl3 or Et2O at 0°, stirring 30 min., keeping overnight, concentrating in vacuo, and distilling the oil (IV) gave O2NOCH2CH2ONO (V), b17 58-60°, d20 1.3053, nD18 1.4240, and O2NOCH2CH2OCH2CH2ONO (VI), b1 84-6°, nD20 1.4350. Adding IV to MeOH released MeONO; refluxing the MeOH solution 2 h. and distilling gave HOCH2CH2ONO2 (VII), b1 65-6°, d21, 1.3395, nD20 1.4410, HOCH2CH2OCH2CH2ONO2 (VIII), b1 95-6°, d21 1.2620, nD20 1.4510, and a fraction, b1 96-119°. IV was obtained in 75% yield (1/3 VII and 1/3 VIII). The reaction proceeded more rapidly in the absence of solvent; using ratios of I to II of 1:1, 2:1, and 3:1 gave 73, 74, and 75% IV containing 40, 43, and 50% VII, resp., and 30, 33, and 35% VIII, resp. II bubbled through I in CHCl3 at 0° gave 50% VII and 42% VIII. Treating I and II in the gaseous phase gave 74% IV, the mononitrate being 63%. Improved yields were obtained by the use of dehydration catalysts, e.g., silica gel. Refluxing II and V 1 h. gave 20% condensed products; heating V at 50° 1 h. gave VII, probably because of moisture, and condensed products; refluxing II and VII I hr. gave 30% condensed products. Heating V and VIII 40 min. at 100° and distilling gave V, VI, VII, and VIII. A mechanism was postulated. Treating VII and VIII with HNO3H2SO4 (50:50) gave (CH2ONO2)2 and O(CH2CH2ONO2)2. Treating VII with AcCl in the presence of C5H5N gave 65% AcOCH2CH2ONO2, b0.7 69.0-9.5°, nD21 1.4290. Similarly VIII gave AcOCH2CH2OCH2CH2ONO2, b0.1 90°, nD20 1.4410. VII and phthalic anhydride at 220° gave a small amount of liquid, b. 95°, which contained the ONO2 group and which polymerized within 24 h. Treating VII with AcOH-CrO3 gave O2NOCH2CO2Me, b16 75°, nD15 1.4221. Treating VII with Me2SO4 and

K2CO3 1 h. at 80-90° gave 10% O2NOCH2CH2OMe, b15 56-60°, nD20 1.415. III added dropwise to 75% I in CHCl3 or Et2O at -5° gave 75% oil, which on distillation gave: nitrite nitrate of propanediol (2 possible isomers) (IX), b22 68-70°, b15 58-9°, nD19 1.4205, d21 1.256; nitrite nitrate of dipropylene glycol (4 possible isomers) (X), b0.3 71-82°, nD20 1.4325; mononitrate of propanediol (2 possible isomers) (XI), b0.1 60-1°, nD19 1.4370, d21 1.234; mononitrate of dipropylene glycol (4 possible isomers) (XII), b0.1 79-80°, nD19 1.4420. Similarly to II, III condensed with IX at 40°; heating this nitrite nitrate 1 h. at 75° gave 31% XI. Nitration of MeCH(OH)CH2OH and of XI gave MeCH(ONO2)CH2ONO2, b0.5 59-60, nD17 1.4475. Nitration of dipropylene glycol and of its mononitrate gave the same dinitrate (2 possible isomers), b0.1 100°, nD15 1.4460, d21 1.2310. Acetylation of XI gave an oil containing a mixture of 2 possible isomers, b16 90°, b0.1 51-3°, nD17 1.4272. Treatment of XI with AcOH-CrO3 gave an oil which on treatment with MeOH in the presence of H2SO4 gave MeCH(ONO2)CO2Me, b16 70-1°, nD19 1.4180, also obtained by nitration of MeCH(OH)CO2Me. Nitration of AcCH2OH in AcOH-CrO3 gave AcCH2ONO2, b0.1 55-63°, nD20 1.431. Treatment of CH:CCH2OH with AcOH in the presence of Hg++ and BF3 in Et2O gave AcCH2OAc, which on hydrogenation over Raney Ni gave MeCH(OH)CH2OAc, and subsequent nitration gave MeCH(ONO2)CH2OAc, b0.1 52-3°, nD17 1.4272. Bromination of EtCHO, treatment of MeCH-BrCHO with KI, acetylation of MeCHICHO with AcOAg, hydrogenation of MeCH(OAc)CHO over Raney Ni, and nitration of MeCH(OAc)CH2OH yielded MeCH(OAc)CH2ONO2, b0.1 48-9°, nD17 1.4268. By means of absorption spectra, it was estimated that IX contained 20% secondary alc. and 80% primary alc.

L13 ANSWER 45 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1957:62089 HCAPLUS
DOCUMENT NUMBER: 51:62089
ORIGINAL REFERENCE NO.: 51:11243d-i,11244a-b
TITLE: Addition of alcohols to octafluoroisobutene
AUTHOR(S): Koshar, Robert J.; Simmons, Thomas C.; Hoffmann, Friedrich W.
CORPORATE SOURCE: Army Chem. Center, MD
SOURCE: Journal of the American Chemical Society (1957), 79, 1741-4
CODEN: JACSAT; ISSN: 0002-7863
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB A gas mixture containing 51 mole-% (CF3)2C:CF2 (I), 27 mole-% octafluorocyclobutane (II), 11.3 mole-% CF3CF:CF2, and 1.5 mole-% hexafluorocyclobutene selectively brominated by the method of Brice, et al. (C.A. 48, 7534i), yielded crude I accompanied by approx. 55% II and other saturated fluorocarbons; this crude I was used in most expts. (CF3)2CBrCF2Br, b. 96°, m. 46°, debrominated in Et2O with Zn by the method of Brice, et al. (loc. cit.), yielded pure I. Pure I (or crude I containing about 45 mole-% I) passed through a 3-mole excess of the appropriate alc. at room temperature at an average flow rate of 0.1 mole I/hr., the system purged with N to remove unreacted I, the mixture washed several times with H2O, and the organic layer dried and distilled gave the corresponding (CF3)2CHCF2OR (III) and (CF3)2C:CFOR (IV) (R, conversion of I, % yield, b.p./mm., nD25, d25, and MRD of III, and % yield, b.p./mm., nD25, d25, and MRD of IV given): Me, 95, 70, 68.5°/760, 1.2809, 1.4931, 27.35, 0, -, -, -, -; Et, 95, 59, 82.0°/760, 1.2909, 1.3982, 32.01, 6,

114.0°/760, 1.3234, 1.3995, 32.36; Pr, 77, 43, 101.5°/760, 1.3047, 1.3463, 36.67, 14, 129.8°/760, 1.3345, 1.339, 37.02; Bu, 70, 52, 53.5°/65, 1.3172, 1.3037, 41.35, 27, 75.0°/53, 1.3449, 1.2933, 41.71; iso-Pr, 80, 35, 43.5°/113, 1.3005, 1.323, 36.75, 26, 45.0°/50, 1.3302, 1.322, 37.04. Cl(CH2)2OH (64 g.) neutralized with 1.5 g. Et3N and treated in the usual manner with 133 g. crude I gave: 54.7 g. H2O-insol. product; 50 g. product fractionated gave 29.5 g. (CF3)2CHCF2O(CH2)2Cl, b160 73.5-4.0°, nD25 1.3292, d25 1.5364, MRD 37.07; 5.0 g. (CF3)2C:C(OCH2CH2Cl)2 (V), b1.7 94°, b3.5 99.0°, nD25 1.4110. Pure I (40 g.) passed into 81 g. Cl(CH2)2OH and 10 g. Et3N below 40° yielded 20 g. unchanged alc. and 17.4 g. V, b3.5 99.0-9.5°, nD25 1.4110. Crude I (115 g.) passed into 68.4 g. CH2:CHCH2OH gave 52 g. crude H2O-insol. product; 45 g. product fractionated yielded 25 g. (CF3)2CHCF2OCH2CH:CH2, b760 100.0°, n25D 1.3135, 1.3893, MRD 36.14, and 6 g. (CF3)2C:C(OCH2CH:CH2)2, b35 75.5°, b40 79°, nD25 1.3727, d25 1.270, MRD 49.46. F(CH2)2OH and I gave in the usual manner 60% (65% conversion) (CF3)2CHCF2OCH2CH2F, b100 64.0°, nD25 1.3018, d25 1.540, MRD 32.24. (CF3)2CHCF2OMe (VI) (35 g.) and 100 cc. 15% aqueous KOH refluxed 20 hrs. at 100°, the organic phase dissolved in Et2O, washed with H2O, dried, and evaporated, and the H2O-insol. residue (26.9 g.) fractionated yielded 7.0 g. unchanged VI and 15.0 g. (CF3)2C:CFOMe, b. 101.5-1.8°. (CF3)2CHCF2OPr (33 g.) and 150 cc. 15% aqueous KOH refluxed 25 hrs. gave similarly 18.0 g. (CF3)2C:CFOPr, b. 129-30°, nD25 1.3345. (CF3)2C:CFOEt (16 g.) added dropwise at room temperature to 12 g. Br with occasional shaking, poured into a large excess aqueous KOH, and shaken, and the crude organic layer (23 g.) worked up yielded 10.2 g. (CF3)2CBrCBrFOEt, b35 75.5°, nD25 1.3906. (CF3)2CHCF2OBu (VII) (24.9 g.) and 40 g. BuOH refluxed 10 hrs., cooled, washed with H2O, dried, and distilled gave 21.5 g. unchanged VII. Na (2.3 g.) in 40-50 cc. absolute EtOH treated with 3.2 cc. H2O, diluted with absolute EtOH to 100 cc., treated with 0.1461 g. (CF3)2CHCF2OEt, and kept 30 hrs. at 24°, and the fluoride ion titrated indicated 93.4% cleavage of all C-F bonds. (CF3)2C:CFOEt (0.1935 g.) liberated similarly during 19 hrs. at 24° 104.8 mg. fluoride ion corresponding to 92.1% decomposition

=> d his

(FILE 'HOME' ENTERED AT 21:58:13 ON 20 SEP 2007)

FILE 'REGISTRY' ENTERED AT 21:58:34 ON 20 SEP 2007

```
L1             STRUCTURE UPLOADED
L2              15 S L1
L3             274 S L1 SSS FULL
L4             STRUCTURE UPLOADED
L5               1 S L4
L6               3 S L4 SSS FULL
L7               0 S L3  SUB=L6 FULL
L8             STRUCTURE UPLOADED
L9               0 S L8
L10              2 S L8 SSS FULL
L11              0 S L3  SUB=L10 FULL
L12              0 S L10  SUB=L3 FULL
```

FILE 'HCAPLUS' ENTERED AT 22:02:54 ON 20 SEP 2007

```
L13             45 S L3
```

=> d l13 1-45 ti

L13 ANSWER 1 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of nitrooxy derivatives as α2 adrenergic receptor agonists

L13 ANSWER 2 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of nitrooxy-comprising derivatives of apraclonidine and brimonidine as α2-adrenergic receptor agonists

L13 ANSWER 3 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of nitrooxy peptidomimetic renin inhibitors for treating cardiovascular, renal and chronic liver diseases, inflammations and metabolic syndrome

L13 ANSWER 4 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of steroid nitrooxy derivatives for use in anti-inflammatory pharmaceutical compositions

L13 ANSWER 5 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Pharmaceutical formulation of nitrooxy derivatives of NSAIDS

L13 ANSWER 6 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Prostaglandin derivatives

L13 ANSWER 7 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of nitrooxy sartan derivatives as angiotensin ii receptor blockers for the treatment of cardiovascular and inflammatory diseases

L13 ANSWER 8 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Identification of a trace colored impurity in drug substance by preparative liquid chromatography and mass spectrometry

L13 ANSWER 9 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Synthesis of a NO-Releasing Prodrug of Rofecoxib

L13 ANSWER 10 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Process for making nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors

L13 ANSWER 11 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of nitric oxide releasing prodrugs of diaryl-2(5H)-furanones as cyclooxygenase-2 inhibitors

L13 ANSWER 12 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of prostaglandin nitrooxy derivatives for the treatment of glaucoma

L13 ANSWER 13 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Nitric oxide-releasing pyruvate compounds, compositions and methods for treating cardiovascular and other diseases

L13 ANSWER 14 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of nitrate esters having a β- or γ-sulfur atom for protection of cells/tissues from oxidative damage.

L13 ANSWER 15 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Nitrosylated analgesic and/or antiinflammatory drugs having antiviral activity

L13 ANSWER 16 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of nitrosated glutamic acid compounds for use in pharmaceutical compositions

L13 ANSWER 17 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of nitro derivatives of heterocyclic compounds as angiotensin II receptor blockers for therapeutic use

L13 ANSWER 18 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Pharmaceutical compositions based on diclofenac derivative

L13 ANSWER 19 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Enalapril-nitroxy derivatives and related compounds as ace inhibitors for the treatment of cardiovascular diseases

L13 ANSWER 20 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of nitrooxy derivatives of fluvastatin, pravastatin, cerivastatin, atorvastatin and rosuvastatin as cholesterol-reducing agents with improved anti-inflammatory, antithrombotic and anti-platelet activity

L13 ANSWER 21 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as selective cyclooxygenase-2 inhibitors

L13 ANSWER 22 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Manufacturing process for NO-donating compounds such as NO-donating diclofenac

L13 ANSWER 23 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of nitrosated nonsteroidal antiinflammatory compounds

L13 ANSWER 24 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability

L13 ANSWER 25 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use

L13 ANSWER 26 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Nitrooxy derivatives of antiinflammatory/analgesic compounds for the treatment of arthritis

L13 ANSWER 27 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Nitric oxide-donating NSAIDS adsorbed into carrier particles

L13 ANSWER 28 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases

L13 ANSWER 29 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Nitric oxide-donating non-steroidal anti-inflammatory drugs: the case of

nitro derivatives of aspirin

L13 ANSWER 30 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Self emulsifying drug delivery system containing NSAIDs

L13 ANSWER 31 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Pharmaceutical compositions containing NO-releasing NSAID and surfactants

L13 ANSWER 32 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI New self emulsifying drug delivery system

L13 ANSWER 33 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Synthesis, activity and formulations of pharmaceutical compounds for treatment of oxidative stress and/or endothelial dysfunction

L13 ANSWER 34 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI New use of compounds as antibacterial agents

L13 ANSWER 35 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Thermal stability of peroxynitrates

L13 ANSWER 36 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of nitric esters of 2-(2,6-dihalophenylamino)phenylacetoxyacetic acid derivatives

L13 ANSWER 37 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of aryl nitrate ester compounds having antiinflammatory ans well as analgesic and antithrombotic activities

L13 ANSWER 38 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Kinetic studies of peroxynitrates and peroxy radicals

L13 ANSWER 39 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Nitroacetic acid ester

L13 ANSWER 40 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Substituted nitroalkyl peroxynitrate

L13 ANSWER 41 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Propellants of pulsed combustion

L13 ANSWER 42 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Solid propellants with pulsatory characteristics

L13 ANSWER 43 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI 1-Nitro-2-nitratopropanes

L13 ANSWER 44 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Action of nitrogen peroxides on epoxides

L13 ANSWER 45 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Addition of alcohols to octafluoroisobutene

=> d l13 1-45 hitstr

L13 ANSWER 1 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN

IT 946403-81-2P 946403-96-9P 946404-19-9P
946404-41-7P 946404-55-3P 946404-60-0P
946404-96-2P 946405-27-2P 946405-52-3P
946405-67-0P 946405-82-9P 946405-97-6P
946406-12-8P 946406-24-2P 946406-25-3P
946406-28-6P 946406-31-1P 946406-32-2P
946406-35-5P 946406-36-6P 946406-39-9P
946406-40-2P 946406-43-5P 946406-44-6P
946406-47-9P 946406-48-0P 946406-51-5P
946406-52-6P 946406-55-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nitrooxy derivs. as α2 adrenergic receptor agonists)

RN 946403-81-2 HCAPLUS
CN 1H-Imidazole-1-carboxylic acid, 2-[(2,6-dichlorophenyl)amino]-4,5-dihydro-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



RN 946403-96-9 HCAPLUS
CN 1H-Imidazole-1-carboxylic acid, 2-[(4-chloro-6-methoxy-2-methyl-5-pyrimidinyl)amino]-4,5-dihydro-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



RN 946404-19-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 946404-41-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 946404-55-3 HCAPLUS
CN 1H-Imidazole-1-carboxylic acid, 2-[(2-chloro-4-methyl-3-thienyl)amino]-4,5-dihydro-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



RN 946404-60-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 946404-96-2 HCAPLUS
CN Tyrosine, α-methyl-O-[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]-3-[[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]oxy]- (CA INDEX NAME)



RN 946405-27-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A



PAGE 1-B



RN 946405-52-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A



PAGE 1-B



RN 946405-67-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A



PAGE 1-B



RN 946405-82-9 HCAPLUS
CN Tyrosine, 3-hydroxy-α-methyl-N-[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]- (CA INDEX NAME)



RN 946405-97-6 HCAPLUS
CN Tyrosine, 3-hydroxy-α-methyl-N-[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]-, ethyl ester (CA INDEX NAME)



RN 946406-12-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 946406-24-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 946406-25-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 946406-28-6 HCAPLUS
CN Tyrosine, 3-hydroxy-α-methyl-N-[[[[2-[3-(nitrooxy)propoxy]ethoxy]carbonyl]oxy]methyl]- (CA INDEX NAME)



RN 946406-31-1 HCAPLUS
CN Tyrosine, 3-hydroxy-α-methyl-N-[[[[2-[3-(nitrooxy)propoxy]ethoxy]carbonyl]oxy]methyl]-, ethyl ester (CA INDEX NAME)



RN 946406-32-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 946406-35-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 946406-36-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 946406-39-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 946406-40-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 946406-43-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 946406-44-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 946406-47-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 946406-48-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 946406-51-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 946406-52-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 946406-55-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



L13 ANSWER 2 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 946393-04-0P 946393-23-3P 946393-40-4P
946393-42-6P 946393-62-0P 946393-63-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nitrooxy-comprising derivs. of apraclonidine and brimonidine as α2-adrenergic receptor agonists)
RN 946393-04-0 HCAPLUS
CN 1H-Imidazole-1-carboxylic acid, 2-[(4-amino-2,6-dichlorophenyl)amino]-4,5-dihydro-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



RN 946393-23-3 HCAPLUS
CN 1H-Imidazole-1-carboxylic acid, 2-[(5-bromo-6-quinoxalinyl)amino]-4,5-dihydro-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



RN 946393-40-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 946393-42-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 946393-62-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 946393-63-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



L13 ANSWER 3 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 935472-19-8P 935472-35-8P 935472-41-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nitrooxy peptidomimetic renin inhibitors useful in combination therapy and prevention of diseases)
RN 935472-19-8 HCAPLUS
CN Carbonic acid, 2-amino-1-[2-[[(3-amino-2,2-dimethyl-3-oxopropyl)amino]carbonyl]-3-methylbutyl]-4-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-5-methylhexyl [2-[2-(nitrooxy)ethoxy]ethyl] ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 935472-35-8 HCAPLUS
CN 2,7,10-Trioxa-5-azadodecanoic acid, 3-[2-[[(3-amino-2,2-dimethyl-3-oxopropyl)amino]carbonyl]-3-methylbutyl]-4-[2-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-3-methylbutyl]-12-(nitrooxy)-6-oxo-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)

PAGE 1-A





PAGE 1-B

RN 935472-41-6 HCAPLUS
CN Carbamic acid, N-[4-[[(3-amino-2,2-dimethyl-3-oxopropyl)amino]carbonyl]-2-hydroxy-1-[2-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-3-methylbutyl]-5-methylhexyl]-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

L13 ANSWER 4 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 928623-94-3P 928624-14-0P 928624-34-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of steroid nitrooxy derivs. for use in anti-inflammatory pharmaceutical compns.)
RN 928623-94-3 HCAPLUS
CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16,17-[(1-methylethylidene)bis(oxy)]-21-[[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]oxy]-, (11β,16α)- (CA INDEX NAME)

Absolute stereochemistry.



RN 928624-14-0 HCAPLUS
CN Pregna-1,4-diene-3,20-dione, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-21-[[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]oxy]-, (11β)- (CA INDEX NAME)

Absolute stereochemistry.



RN 928624-34-4 HCAPLUS
CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-21-[[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]oxy]-17-[(1-oxopentyl)oxy]-, (11β,16β)- (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 5 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 174454-43-4 174454-51-4 311336-59-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical formulation of nitrooxy derivs. of NSAIDS)
RN 174454-43-4 HCAPLUS
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



RN 174454-51-4 HCAPLUS
CN 2-Naphthaleneacetic acid, 6-methoxy-α-methyl-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



RN 311336-59-1 HCAPLUS
CN Benzeneacetic acid, 3-benzoyl-α-methyl-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



L13 ANSWER 6 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 918341-76-1P 918341-78-3P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of prostaglandin derivs. containing a nitrooxy
moiety for therapeutic use in the treatment of glaucoma and ocular hypertension)
RN 918341-76-1 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl]-, 2-[2-(nitrooxy)ethoxy]ethyl ester, (5Z)-(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 918341-78-3 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl]-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester, (5Z)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L13 ANSWER 7 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 902123-41-5P 902123-42-6P 902123-61-9P
902123-62-0P 902123-63-1P 902123-64-2P
902124-01-0P 902124-02-1P 902124-03-2P
902124-04-3P 902124-06-5P 902124-07-6P
902124-33-8P 902124-34-9P 902124-35-0P
902124-55-4P 902124-56-5P 902124-57-6P
902124-58-7P 902124-74-7P 902124-75-8P
902125-06-8P 902125-07-9P 902125-08-0P
902125-09-1P 902125-11-5P 902125-12-6P
902125-30-8P 902125-31-9P 902125-41-1P
902125-42-2P 902125-51-3P 902125-54-6P
902125-71-7P 902125-72-8P 902125-78-4P
902125-79-5P 902125-89-7P 902125-90-0P
902126-04-9P 902126-05-0P 902126-15-2P
902126-16-3P 902126-26-5P 902126-27-6P
902126-64-1P 902126-65-2P 902126-66-3P
902126-67-4P 902126-92-5P 902126-93-6P
902126-94-7P 902126-95-8P 902126-97-0P
902126-98-1P 902127-16-6P 902127-17-7P
902127-18-8P 902127-19-9P 902127-38-2P
902127-39-3P 902127-50-8P 902127-80-4P
902127-81-5P 902127-82-6P 902127-83-7P
902128-08-9P 902128-09-0P 902128-25-0P
902128-26-1P 902128-34-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nitrooxy sartan derivs. as angiotensin ii receptor blockers for the treatment of cardiovascular and inflammatory diseases)
RN 902123-41-5 HCAPLUS
CN 2H-Tetrazole-2-carboxylic acid, 5-[4'-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



RN 902123-42-6 HCAPLUS
CN 2H-Tetrazole-2-carboxylic acid, 5-[4'-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (CA INDEX NAME)



RN 902123-61-9 HCAPLUS
CN L-Valine, N-[[2'-[2-[[[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]oxy]methyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-N-(1-oxopentyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 902123-62-0 HCAPLUS
CN L-Valine, N-[[2'-[2-[1-[[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]oxy]ethyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-N-(1-oxopentyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 902123-63-1 HCAPLUS
CN L-Valine, N-[[2'-[2-[[[[2-[[2-(nitrooxy)ethyl]thio]ethoxy]carbonyl]oxy]methyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-N-(1-oxopentyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 902123-64-2 HCAPLUS
CN L-Valine, N-[[2'-[2-[1-[[[2-[[2-(nitrooxy)ethyl]thio]ethoxy]carbonyl]oxy]ethyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-N-(1-oxopentyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 902124-01-0 HCAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-[2-[[[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]oxy]methyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 902124-02-1 HCAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-[2-[1-[[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]oxy]ethyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 902124-03-2 HCAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-[2-[[[[2-[[2-(nitrooxy)ethyl]thio]ethoxy]carbonyl]oxy]methyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 902124-04-3 HCAPLUS

CN 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-[2-[1-[[[2-[[2-(nitrooxy)ethyl]thio]ethoxy]carbonyl]oxy]ethyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 902124-06-5 HCAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-[2-[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 902124-07-6 HCAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-[2-[[2-[[2-(nitrooxy)ethyl]thio]ethoxy]carbonyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 902124-33-8 HCAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-[2-[[[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]oxy]methyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-, 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—NO_2

PAGE 2-A



RN 902124-34-9 HCAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-[2-[[[[2-[[2-(nitrooxy)ethyl]thio]ethoxy]carbonyl]oxy]methyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-, 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—NO_2

PAGE 2-A



RN 902124-35-0 HCAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-[2-[1-[[[2-[[2-(nitrooxy)ethyl]thio]ethoxy]carbonyl]oxy]ethyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-, 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester (CA INDEX NAME)

PAGE 1-A





RN 902124-55-4 HCAPLUS
CN Carbonic acid, [5-[4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl][1,1'-biphenyl]-2-yl]-2H-tetrazol-2-yl]methyl 2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)



RN 902124-56-5 HCAPLUS
CN Carbonic acid, [5-[4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl][1,1'-biphenyl]-2-yl]-2H-tetrazol-2-yl]methyl 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (9CI) (CA INDEX NAME)



RN 902124-57-6 HCAPLUS
CN Carbonic acid, 1-[5-[4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl][1,1'-biphenyl]-2-yl]-2H-tetrazol-2-yl]ethyl

2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)



RN 902124-58-7 HCAPLUS
CN Carbonic acid, 1-[5-[4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl][1,1'-biphenyl]-2-yl]-2H-tetrazol-2-yl]ethyl 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (9CI) (CA INDEX NAME)



RN 902124-74-7 HCAPLUS
CN 2H-Tetrazole-2-carboxylic acid, 5-[4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl][1,1'-biphenyl]-2-yl]-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



RN 902124-75-8 HCAPLUS
CN 2H-Tetrazole-2-carboxylic acid, 5-[4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl][1,1'-biphenyl]-2-yl]-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (CA INDEX NAME)



RN 902125-06-8 HCAPLUS
CN 1H-Imidazole-5-carboxylic acid, 2-butyl-4-chloro-1-[[2'-[2-[1-[[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]oxy]ethyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 902125-07-9 HCAPLUS
CN 1H-Imidazole-5-carboxylic acid, 2-butyl-4-chloro-1-[[2'-[2-[[[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]oxy]methyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 902125-08-0 HCAPLUS
CN 1H-Imidazole-5-carboxylic acid, 2-butyl-4-chloro-1-[[2'-[2-[1-[[[2-[[2-(nitrooxy)ethyl]thio]ethoxy]carbonyl]oxy]ethyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 902125-09-1 HCAPLUS
CN 1H-Imidazole-5-carboxylic acid, 2-butyl-4-chloro-1-[[2'-[2-[[[[2-[[2-(nitrooxy)ethyl]thio]ethoxy]carbonyl]oxy]methyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 902125-11-5 HCAPLUS
CN 2H-Tetrazole-2-carboxylic acid, 5-[4'-[(2-butyl-5-carboxy-4-chloro-1H-imidazol-1-yl)methyl][1,1'-biphenyl]-2-yl]-, 2-[2-[2-(nitrooxy)ethoxy]ethyl] ester (CA INDEX NAME)



RN 902125-12-6 HCAPLUS
CN 2H-Tetrazole-2-carboxylic acid, 5-[4'-[(2-butyl-5-carboxy-4-chloro-1H-imidazol-1-yl)methyl][1,1'-biphenyl]-2-yl]-, 2-[2-[[2-(nitrooxy)ethyl]thio]ethyl] ester (CA INDEX NAME)



RN 902125-30-8 HCAPLUS
CN 2H-Tetrazole-2-carboxylic acid, 5-[4'-[[5-carboxy-4-(1-hydroxy-1-methylethyl)-2-propyl-1H-imidazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-, 2-[2-[2-(nitrooxy)ethoxy]ethyl] ester (CA INDEX NAME)



RN 902125-31-9 HCAPLUS
CN 2H-Tetrazole-2-carboxylic acid, 5-[4'-[[5-carboxy-4-(1-hydroxy-1-methylethyl)-2-propyl-1H-imidazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-, 2-[2-[[2-(nitrooxy)ethyl]thio]ethyl] ester (CA INDEX NAME)



RN 902125-41-1 HCAPLUS
CN 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-1-[[2'-[2-[[[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]oxy]methyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-2-propyl- (CA INDEX NAME)



RN 902125-42-2 HCAPLUS
CN 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-1-[[2'-[2-[[[[2-[[2-(nitrooxy)ethyl]thio]ethoxy]carbonyl]oxy]methyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-2-propyl- (CA INDEX NAME)



RN 902125-51-3 HCAPLUS
CN 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-1-[[2'-[2-[1-[[[2-[[2-(nitrooxy)ethyl]thio]ethoxy]carbonyl]oxy]ethyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-2-propyl- (CA INDEX NAME)



RN 902125-54-6 HCAPLUS
CN 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-1-[[2'-[2-[1-[[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]oxy]ethyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-2-propyl- (CA INDEX NAME)



RN 902125-71-7 HCAPLUS
CN 2H-Tetrazole-2-carboxylic acid, 5-[4'-[[4-(1-hydroxy-1-methylethyl)-5-[[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]carbonyl]-2-propyl-1H-imidazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



RN 902125-72-8 HCAPLUS
CN 2H-Tetrazole-2-carboxylic acid, 5-[4'-[[4-(1-hydroxy-1-methylethyl)-5-[[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]carbonyl]-2-propyl-1H-imidazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (CA INDEX NAME)



RN 902125-78-4 HCAPLUS
CN 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-1-[[2'-[2-[[[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]oxy]methyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-2-propyl-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 902125-79-5 HCAPLUS
CN 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-1-[[2'-[2-[[[[2-[[2-(nitrooxy)ethyl]thio]ethoxy]carbonyl]oxy]methyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-2-propyl-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 902125-89-7 HCAPLUS
CN 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxyethyl)-1-[[2'-[2-[1-[[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]oxy]ethyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-2-propyl-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 902125-90-0 HCAPLUS
CN 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-1-[[2'-[2-[1-[[[2-[[2-(nitrooxy)ethyl]thio]ethoxy]carbonyl]oxy]ethyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-2-propyl-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—Me

RN 902126-04-9 HCAPLUS
CN 2H-Tetrazole-2-carboxylic acid, 5-[4'-[(6,7-dihydro-2,4-dimethyl-7-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)methyl][1,1'-biphenyl]-2-yl]-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



RN 902126-05-0 HCAPLUS
CN 2H-Tetrazole-2-carboxylic acid, 5-[4'-[(6,7-dihydro-2,4-dimethyl-7-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)methyl][1,1'-biphenyl]-2-yl]-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (CA INDEX NAME)



RN 902126-15-2 HCAPLUS
CN Carbonic acid, [5-[4'-[(6,7-dihydro-2,4-dimethyl-7-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)methyl][1,1'-biphenyl]-2-yl]-2H-tetrazol-2-yl]methyl 2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)



RN 902126-16-3 HCAPLUS
CN Carbonic acid, [5-[4'-[(6,7-dihydro-2,4-dimethyl-7-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)methyl][1,1'-biphenyl]-2-yl]-2H-tetrazol-2-yl]methyl 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (9CI) (CA INDEX NAME)



RN 902126-26-5 HCAPLUS
CN Carbonic acid, 1-[5-[4'-[(6,7-dihydro-2,4-dimethyl-7-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)methyl][1,1'-biphenyl]-2-yl]-2H-tetrazol-2-yl]ethyl 2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)



RN 902126-27-6 HCAPLUS
CN Carbonic acid, 1-[5-[4'-[(6,7-dihydro-2,4-dimethyl-7-oxopyrido[2,3-d]pyrimidin-8(5H)-yl)methyl][1,1'-biphenyl]-2-yl]-2H-tetrazol-2-yl]ethyl 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (9CI) (CA INDEX NAME)



RN 902126-64-1 HCAPLUS
CN 1H-Imidazole-5-carboxylic acid, 1-[[2'-[2-[1-[[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]oxy]ethyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-4-(pentafluoroethyl)-2-propyl- (9CI) (CA INDEX NAME)



RN 902126-65-2 HCAPLUS
CN 1H-Imidazole-5-carboxylic acid, 1-[[2'-[2-[[[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]oxy]methyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-4-(pentafluoroethyl)-2-propyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 902126-66-3 HCAPLUS
CN 1H-Imidazole-5-carboxylic acid, 1-[[2'-[2-[1-[[[2-[[2-(nitrooxy)ethyl]thio]ethoxy]carbonyl]oxy]ethyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-4-(pentafluoroethyl)-2-propyl- (9CI) (CA INDEX NAME)



RN 902126-67-4 HCAPLUS

CN 1H-Imidazole-5-carboxylic acid, 1-[[2'-[2-[[[[2-[[2-(nitrooxy)ethyl]thio]ethoxy]carbonyl]oxy]methyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-4-(pentafluoroethyl)-2-propyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—NO_2

RN 902126-92-5 HCAPLUS
CN 1H-Imidazole-5-carboxylic acid, 2-butyl-4-chloro-1-[[2'-[2-[1-[[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]oxy]ethyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-, 1-[(ethoxycarbonyl)oxy]ethyl ester (CA INDEX NAME)



RN 902126-93-6 HCAPLUS
CN 1H-Imidazole-5-carboxylic acid, 2-butyl-4-chloro-1-[[2'-[2-[[[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]oxy]methyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-, 1-[(ethoxycarbonyl)oxy]ethyl ester (CA INDEX NAME)



RN 902126-94-7 HCAPLUS
CN 1H-Imidazole-5-carboxylic acid, 2-butyl-4-chloro-1-[[2'-[2-[1-[[[2-[[2-(nitrooxy)ethyl]thio]ethoxy]carbonyl]oxy]ethyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-, 1-[(ethoxycarbonyl)oxy]ethyl ester (CA INDEX NAME)



RN 902126-95-8 HCAPLUS
CN 1H-Imidazole-5-carboxylic acid, 2-butyl-4-chloro-1-[[2'-[2-[[[[2-[[2-(nitrooxy)ethyl]thio]ethoxy]carbonyl]oxy]methyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-, 1-[(ethoxycarbonyl)oxy]ethyl ester (CA INDEX NAME)



RN 902126-97-0 HCAPLUS
CN 2H-Tetrazole-2-carboxylic acid, 5-[4'-[[2-butyl-4-chloro-5-[[1-[(ethoxycarbonyl)oxy]ethoxy]carbonyl]-1H-imidazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



RN 902126-98-1 HCAPLUS
CN 2H-Tetrazole-2-carboxylic acid, 5-[4'-[[2-butyl-4-chloro-5-[[1-[(ethoxycarbonyl)oxy]ethoxy]carbonyl]-1H-imidazol-1-yl]methyl][1,1'-biphenyl]-2-yl]-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (CA INDEX NAME)



RN 902127-16-6 HCAPLUS
CN Carbonic acid, [5-[4'-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl][1,1'-biphenyl]-2-yl]-2H-tetrazol-2-yl]methyl 2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)



RN 902127-17-7 HCAPLUS
CN Carbonic acid, [5-[4'-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl][1,1'-biphenyl]-2-yl]-2H-tetrazol-2-yl]methyl 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (9CI) (CA INDEX NAME)



RN 902127-18-8 HCAPLUS
CN Carbonic acid, 1-[5-[4'-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl][1,1'-biphenyl]-2-yl]-2H-tetrazol-2-yl]ethyl 2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)



RN 902127-19-9 HCAPLUS
CN Carbonic acid, 1-[5-[4'-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl][1,1'-biphenyl]-2-yl]-2H-tetrazol-2-yl]ethyl 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (9CI) (CA INDEX NAME)



RN 902127-38-2 HCAPLUS
CN 2H-Tetrazole-2-carboxylic acid, 5-[4'-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl][1,1'-biphenyl]-2-yl]-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



RN 902127-39-3 HCAPLUS
CN 2H-Tetrazole-2-carboxylic acid, 5-[4'-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl][1,1'-biphenyl]-2-yl]-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (CA INDEX NAME)



RN 902127-50-8 HCAPLUS
CN 2H-Tetrazole-2-carboxylic acid, 5-[4'-[[[(1S)-2-methyl-1-[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]propyl](1-oxopentyl)amino]methyl][1,1'-biphenyl]-2-yl]-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 902127-80-4 HCAPLUS
CN L-Valine, N-[[2'-[2-[[[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]oxy]methyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-N-(1-oxopentyl)-, 4-(nitrooxy)butyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 902127-81-5 HCAPLUS
CN L-Valine, N-[[2'-[2-[1-[[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]oxy]ethyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-N-(1-oxopentyl)-, 4-(nitrooxy)butyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 902127-82-6 HCAPLUS
CN L-Valine, N-[[2'-[2-[[[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]oxy]methyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-N-(1-oxopentyl)-, 3-[(nitrooxy)methyl]phenyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 902127-83-7 HCAPLUS
CN L-Valine, N-[[2'-[2-[1-[[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]oxy]ethyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-N-(1-oxopentyl)-, 3-[(nitrooxy)methyl]phenyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 902128-08-9 HCAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-[2-[1-[[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]oxy]ethyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-, 1-[[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]oxy]ethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 902128-09-0 HCAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-[2-[[[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]oxy]methyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-, [[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]oxy]methyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 902128-25-0 HCAPLUS
CN 1H-Imidazole-5-carboxylic acid, 2-butyl-4-chloro-1-[[2'-[2-[1-[[[2-[2-

(nitrooxy)ethoxy]ethoxy]carbonyl]oxy]ethyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-, 4-(nitrooxy)butyl ester (CA INDEX NAME)



RN 902128-26-1 HCAPLUS
CN 1H-Imidazole-5-carboxylic acid, 2-butyl-4-chloro-1-[[2'-[2-[1-[[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]oxy]ethyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-, 3-(nitrooxy)propyl ester (CA INDEX NAME)



RN 902128-34-1 HCAPLUS
CN 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-1-[[2'-[2-[1-[[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]oxy]ethyl]-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-2-propyl-, 4-(nitrooxy)butyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L13 ANSWER 8 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 754241-98-0
RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(identification of colored impurity in drug substance by preparative HPLC)
RN 754241-98-0 HCAPLUS
CN Benzeneacetic acid, α-[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 6-(nitrooxy)hexyl ester, (αZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L13 ANSWER 9 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 754241-98-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of a NO-releasing prodrug of rofecoxib in five chemical steps from 3-phenyl-2-propyn-1-ol)
RN 754241-98-0 HCAPLUS
CN Benzeneacetic acid, α-[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 6-(nitrooxy)hexyl ester, (αZ)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



L13 ANSWER 10 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 754241-98-0P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors)
RN 754241-98-0 HCAPLUS
CN Benzeneacetic acid, α-[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 6-(nitrooxy)hexyl ester, (αZ)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



L13 ANSWER 11 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 861655-83-6P 861655-84-7P 861655-85-8P
861655-86-9P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nitric oxide releasing prodrugs of diaryl-2(5H)-furanones as cyclooxygenase-2 inhibitors)
RN 861655-83-6 HCAPLUS
CN Benzeneacetic acid, α-[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 5,6-bis(nitrooxy)hexyl ester, (αZ)- (CA INDEX NAME)

Double bond geometry as shown.



RN 861655-84-7 HCAPLUS
CN Benzeneacetic acid, α-[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, (5R)-5,6-bis(nitrooxy)hexyl ester, (αZ)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 861655-85-8 HCAPLUS
CN Benzeneacetic acid, α-[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 4,5-bis(nitrooxy)pentyl ester, (αZ)- (CA INDEX NAME)

Double bond geometry as shown.



RN 861655-86-9 HCAPLUS
CN Benzeneacetic acid, α-[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 3,4-bis(nitrooxy)butyl ester, (αZ)- (CA INDEX NAME)

Double bond geometry as shown.



L13 ANSWER 12 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 860005-22-7P 860005-23-8P 860005-35-2P
860005-36-3P 860005-41-0P 860005-42-1P
860005-53-4P 860005-54-5P 860005-59-0P
860005-60-3P 860005-71-6P 860005-72-7P
860005-77-2P 860005-78-3P 860005-89-6P

860005-90-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of prostaglandin nitrooxy derivs. for treatment of glaucoma)

RN 860005-22-7 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-, 2-[2-(nitrooxy)ethoxy]ethyl ester, (5Z)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Ph

RN 860005-23-8 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester, (5Z)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Ph

RN 860005-35-2 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-, 3-(nitrooxy)-2-[4-(nitrooxy)-1-oxobutoxy]propyl ester, (5Z)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Ph

RN 860005-36-3 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-, 3-(nitrooxy)-2-[2-(nitrooxy)ethoxy]propyl ester, (5Z)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 860005-41-0 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-butenyl]cyclopentyl]-, 2-[2-(nitrooxy)ethoxy]ethyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 860005-42-1 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-butenyl]cyclopentyl]-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 860005-53-4 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-butenyl]cyclopentyl]-, 3-(nitrooxy)-2-[4-(nitrooxy)-1-oxobutoxy]propyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 860005-54-5 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-butenyl]cyclopentyl]-, 3-(nitrooxy)-2-[2-(nitrooxy)ethoxy]propyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 860005-59-0 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-2-[(1E,3R)-4-(3-chlorophenoxy)-3-hydroxy-1-butenyl]-3,5-dihydroxycyclopentyl]-, 2-[2-(nitrooxy)ethoxy]ethyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 860005-60-3 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-2-[(1E,3R)-4-(3-chlorophenoxy)-3-hydroxy-1-butenyl]-3,5-dihydroxycyclopentyl]-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 860005-71-6 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-2-[(1E,3R)-4-(3-chlorophenoxy)-3-hydroxy-1-butenyl]-3,5-dihydroxycyclopentyl]-, 3-(nitrooxy)-2-[4-(nitrooxy)-1-oxobutoxy]propyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 860005-72-7 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-2-[(1E,3R)-4-(3-chlorophenoxy)-3-hydroxy-1-butenyl]-3,5-dihydroxycyclopentyl]-, 3-(nitrooxy)-2-[2-(nitrooxy)ethoxy]propyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 860005-77-2 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-, 2-[2-(nitrooxy)ethoxy]ethyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 860005-78-3 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 860005-89-6 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-, 3-(nitrooxy)-2-[4-(nitrooxy)-1-oxobutoxy]propyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





RN 860005-90-9 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-, 3-(nitrooxy)-2-[2-(nitrooxy)ethoxy]propyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L13 ANSWER 13 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 857465-04-4P 857465-05-5P 857465-25-9P
857465-26-0P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nitric oxide-releasing pyruvate compds. and compns. for treating cardiovascular and other diseases)
RN 857465-04-4 HCAPLUS
CN L-Glutamic acid, 5-[(2S)-3-[(2R)-2,3-bis(nitrooxy)propoxy]-2-[(1,2-dioxopropyl)amino]-3-oxopropyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 857465-05-5 HCAPLUS
CN L-Glutamic acid, 5-[(2S)-3-[(2S)-2,3-bis(nitrooxy)propoxy]-2-[(1,2-dioxopropyl)amino]-3-oxopropyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 857465-25-9 HCAPLUS
CN L-Serine, L-γ-glutamyl-, 2-[(2R)-2,3-bis(nitrooxy)propyl] ester, 2-oxopropanoate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 857465-26-0 HCAPLUS
CN L-Serine, L-γ-glutamyl-, 2-[(2S)-2,3-bis(nitrooxy)propyl] ester, 2-oxopropanoate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 14 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 854925-82-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of nitrate esters having β- or γ-sulfur atom for protection of cells/tissues from oxidative damage)
RN 854925-82-9 HCAPLUS
CN 2H-1-Benzopyran-2-carboxylic acid, 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-, 2-[[2,3-bis(nitrooxy)propyl]thio]ethyl ester (9CI) (CA INDEX NAME)



L13 ANSWER 15 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 174454-51-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nitrosylated analgesic and/or antiinflammatory drugs having antiviral activity)
RN 174454-51-4 HCAPLUS
CN 2-Naphthaleneacetic acid, 6-methoxy-α-methyl-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



L13 ANSWER 16 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 849138-32-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nitrosated glutamic acid compds. for use in pharmaceutical compns.)
RN 849138-32-5 HCAPLUS
CN L-Glutamic acid, 5-[2-[[2-(nitrooxy)ethyl]sulfonyl]ethyl] ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 849138-62-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of nitrosated glutamic acid compds. for use in pharmaceutical compns.)
RN 849138-62-1 HCAPLUS
CN L-Glutamic acid, N-[(1,1-dimethylethoxy)carbonyl]-, 1-(1,1-dimethylethyl) 5-[2-[[2-(nitrooxy)ethyl]sulfonyl]ethyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 17 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 838876-44-1 838876-47-4 838877-11-5
838877-15-9 838877-26-2 838877-30-8
838877-74-0 838877-77-3 838878-05-0
838878-07-2 838878-41-4 838878-43-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of nitro derivs. of heterocyclic compds. as angiotensin II receptor blockers for therapeutic use)
RN 838876-44-1 HCAPLUS
CN 1H-Imidazole-5-carboxylic acid, 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)



RN 838876-47-4 HCAPLUS
CN 1H-Imidazole-5-carboxylic acid, 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (9CI) (CA INDEX NAME)



RN 838877-11-5 HCAPLUS
CN L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 838877-15-9 HCAPLUS
CN L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 838877-26-2 HCAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)



RN 838877-30-8 HCAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (9CI) (CA INDEX NAME)



RN 838877-74-0 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,4'-dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-, 2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)



RN 838877-77-3 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,4'-dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (9CI) (CA INDEX NAME)



RN 838878-05-0 HCAPLUS
CN 2-Thiophenepropanoic acid, α-[[2-butyl-1-[[4-[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]phenyl]methyl]-1H-imidazol-5-yl]methylene]-, mono[2-[2-(nitrooxy)ethoxy]ethyl] ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 838878-07-2 HCAPLUS
CN 2-Thiophenepropanoic acid, α-[[2-butyl-1-[[4-[[2-[[2-(nitrooxy)ethyl]thio]ethoxy]carbonyl]phenyl]methyl]-1H-imidazol-5-yl]methylene]-, mono[2-[[2-(nitrooxy)ethyl]thio]ethyl] ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 838878-41-4 HCAPLUS
CN 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)



RN 838878-43-6 HCAPLUS
CN 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (9CI) (CA INDEX NAME)



L13 ANSWER 18 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 174454-43-4
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(porous particle compns. comprising NO-donating diclofenac derivative)
RN 174454-43-4 HCAPLUS
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



L13 ANSWER 19 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 811787-89-0P 811787-90-3P 811787-91-4P
811787-92-5P 811787-93-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(enalapril-nitroxy derivs. and related compound as ACE inhibitors for the treatment of cardiovascular and renal diseases)
RN 811787-89-0 HCAPLUS
CN Benzenebutanoic acid, α-[[(1,1-dimethylethoxy)carbonyl]amino]-, 2-[2-(nitrooxy)ethoxy]ethyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811787-90-3 HCAPLUS
CN Benzenebutanoic acid, α-amino-, 2-[2-(nitrooxy)ethoxy]ethyl ester, monohydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 811787-91-4 HCAPLUS
CN L-Proline, N-[(1S)-1-[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]-3-phenylpropyl]-L-alanyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811787-92-5 HCAPLUS
CN L-Proline, N-[(1S)-1-[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]-3-phenylpropyl]-L-alanyl-, 1,1-dimethylethyl ester, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811787-91-4
CMF C26 H39 N3 O9

Absolute stereochemistry.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 811787-93-6 HCAPLUS
CN L-Proline, N-[(1S)-1-[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]-3-phenylpropyl]-L-alanyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 811786-20-6 811786-21-7 811786-25-1
811786-26-2 811786-30-8 811786-32-0
811786-40-0 811786-41-1 811786-46-6
811786-47-7 811786-48-8 811786-49-9
811786-50-2 811786-51-3 811786-55-7
811786-56-8 811786-60-4 811786-61-5
811786-65-9 811786-66-0 811786-70-6
811786-71-7 811786-75-1 811786-76-2
811786-80-8 811786-81-9 811786-86-4
811786-87-5 811786-91-1 811786-92-2
811786-96-6 811786-97-7 811787-11-8
811787-13-0 811787-19-6 811787-21-0
811787-27-6 811787-29-8 811787-38-9
811787-39-0 811787-43-6 811787-44-7
811787-48-1 811787-49-2 811787-54-9
811787-55-0 811787-60-7 811787-61-8
811787-67-4 811787-68-5 811787-72-1
811787-73-2 811787-74-3 812681-86-0
812681-87-1 812681-91-7 812681-92-8
812681-96-2 812681-97-3 812682-01-2
812682-02-3 812682-06-7 812682-07-8
812682-11-4
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(enalapril-nitroxy derivs. and related compound as ACE inhibitors for the treatment of cardiovascular and renal diseases)

RN 811786-20-6 HCAPLUS
CN L-Proline, N-[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl-, 2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811786-21-7 HCAPLUS
CN L-Proline, N-[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811786-25-1 HCAPLUS
CN 4-Imidazolidinecarboxylic acid, 3-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-, 2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811786-26-2 HCAPLUS

CN 4-Imidazolidinecarboxylic acid, 3-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811786-30-8 HCAPLUS
CN 3-Isoquinolinecarboxylic acid, 2-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-, 2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811786-32-0 HCAPLUS
CN 3-Isoquinolinecarboxylic acid, 2-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811786-40-0 HCAPLUS
CN 3-Isoquinolinecarboxylic acid, 2-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-, 2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811786-41-1 HCAPLUS
CN 3-Isoquinolinecarboxylic acid, 2-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 811786-46-6 HCAPLUS
CN 1,4-Dithia-7-azaspiro[4.4]nonane-8-carboxylic acid, 7-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-, 2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 811786-47-7 HCAPLUS
CN 1,4-Dithia-7-azaspiro[4.4]nonane-8-carboxylic acid, 7-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 811786-48-8 HCAPLUS
CN L-Proline, 1-[3-(acetylthio)-2-methyl-1-oxopropyl]-, 2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811786-49-9 HCAPLUS
CN L-Proline, 1-[3-(acetylthio)-2-methyl-1-oxopropyl]-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811786-50-2 HCAPLUS
CN L-Phenylalanine, 1-[(2S)-3-(acetylthio)-2-methyl-1-oxopropyl]-L-prolyl-,

2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811786-51-3 HCAPLUS
CN L-Phenylalanine, 1-[(2S)-3-(acetylthio)-2-methyl-1-oxopropyl]-L-prolyl-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811786-55-7 HCAPLUS
CN L-Proline, N-(cyclohexylcarbonyl)-L-alanyl-3-mercapto-2-methylpropanoyl-, 2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811786-56-8 HCAPLUS
CN L-Proline, N-(cyclohexylcarbonyl)-L-alanyl-3-mercapto-2-methylpropanoyl-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811786-60-4 HCAPLUS
CN L-Proline, N-[(1S)-1-[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]-3-phenylpropyl]-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811786-61-5 HCAPLUS
CN L-Proline, N-[(1S)-1-[[2-[[2-(nitrooxy)ethyl]thio]ethoxy]carbonyl]-3-phenylpropyl]-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811786-65-9 HCAPLUS
CN 4-Imidazolidinecarboxylic acid, 1-methyl-3-[(2S)-2-[[(1S)-1-[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]-3-phenylpropyl]amino]-1-oxopropyl]-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811786-66-0 HCAPLUS
CN 4-Imidazolidinecarboxylic acid, 1-methyl-3-[(2S)-2-[[(1S)-1-[[2-[[2-(nitrooxy)ethyl]thio]ethoxy]carbonyl]-3-phenylpropyl]amino]-1-oxopropyl]-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811786-70-6 HCAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2,3,4-tetrahydro-2-[(2S)-2-[[(1S)-1-[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]-3-phenylpropyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811786-71-7 HCAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2,3,4-tetrahydro-2-[(2S)-2-[[(1S)-1-[[2-

[[2-(nitrooxy)ethyl]thio]ethoxy]carbonyl]-3-phenylpropyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811786-75-1 HCAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-[(2S)-2-[[(1S)-1-[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]-3-phenylpropyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811786-76-2 HCAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-[(2S)-2-[[(1S)-1-[[2-[[2-(nitrooxy)ethyl]thio]ethoxy]carbonyl]-3-phenylpropyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811786-80-8 HCAPLUS
CN 1,4-Dithia-7-azaspiro[4.4]nonane-8-carboxylic acid, 7-[(2S)-2-[[(1S)-1-[[2-

[2-(nitrooxy)ethoxy]ethoxy]carbonyl]-3-phenylpropyl]amino]-1-oxopropyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811786-81-9 HCAPLUS
CN 1,4-Dithia-7-azaspiro[4.4]nonane-8-carboxylic acid, 7-[(2S)-2-[[(1S)-1-[[2-[[2-(nitrooxy)ethyl]thio]ethoxy]carbonyl]-3-phenylpropyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811786-86-4 HCAPLUS
CN L-Proline, N2-[(1S)-1-[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]-3-phenylpropyl]-L-lysyl-, 2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—NO_2

RN 811786-87-5 HCAPLUS
CN L-Proline, N2-[(1S)-1-[[2-[[2-(nitrooxy)ethyl]thio]ethoxy]carbonyl]-3-phenylpropyl]-L-lysyl-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—NO_2

RN 811786-91-1 HCAPLUS
CN L-Proline, N-[(1S)-1-[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]-3-phenylpropyl]-L-alanyl-, 2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—NO_2

RN 811786-92-2 HCAPLUS
CN L-Proline, N-[(1S)-1-[[2-[[2-(nitrooxy)ethyl]thio]ethoxy]carbonyl]-3-phenylpropyl]-L-alanyl-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—NO_2

RN 811786-96-6 HCAPLUS
CN L-Proline, N2-[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-lysyl-, 2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811786-97-7 HCAPLUS
CN L-Proline, N2-[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-lysyl-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811787-11-8 HCAPLUS
CN L-Proline, N2-[(1S)-1-carboxy-3-phenylpropyl]-N6-[[4-(nitrooxy)butoxy]carbonyl]-L-lysyl-, 2-[2-[[2-(nitrooxy)ethyl]thio]ethyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 811787-13-0 HCAPLUS
CN L-Proline, N2-[(1S)-1-carboxy-3-phenylpropyl]-N6-[[4-(nitrooxy)butoxy]carbonyl]-L-lysyl-, 2-[2-[2-(nitrooxy)ethoxy]ethyl] ester

(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 811787-19-6 HCAPLUS
CN L-Proline, N2-[(1S)-1-carboxy-3-phenylpropyl]-N6-[[(nitrooxy)methoxy]carbonyl]-L-lysyl-, 2-[2-[2-(nitrooxy)ethoxy]ethyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811787-21-0 HCAPLUS
CN L-Proline, N2-[(1S)-1-carboxy-3-phenylpropyl]-N6-[[(nitrooxy)methoxy]carbonyl]-L-lysyl-, 2-[2-[[2-

(nitrooxy)ethyl]thio]ethyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811787-27-6 HCAPLUS
CN L-Proline, N2-[(1S)-1-carboxy-3-phenylpropyl]-N6-[[1-(nitrooxy)ethoxy]carbonyl]-L-lysyl-, 2-[2-[2-(nitrooxy)ethoxy]ethyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811787-29-8 HCAPLUS
CN L-Proline, N2-[(1S)-1-carboxy-3-phenylpropyl]-N6-[[1-(nitrooxy)ethoxy]carbonyl]-L-lysyl-, 2-[2-[[2-(nitrooxy)ethyl]thio]ethyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811787-38-9 HCAPLUS
CN L-Proline, N-[(1S)-1-carboxy-3-phenylpropyl]-L-alanyl-, 2-[2-[2-(nitrooxy)ethoxy]ethyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811787-39-0 HCAPLUS
CN L-Proline, N-[(1S)-1-carboxy-3-phenylpropyl]-L-alanyl-, 2-[2-[[2-(nitrooxy)ethyl]thio]ethyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811787-43-6 HCAPLUS
CN 4-Imidazolidinecarboxylic acid, 3-[(2S)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-, 4-[2-[2-

(nitrooxy)ethoxy]ethyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811787-44-7 HCAPLUS
CN 4-Imidazolidinecarboxylic acid, 3-[(2S)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-, 4-[2-[[2-(nitrooxy)ethyl]thio]ethyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811787-48-1 HCAPLUS
CN 3-Isoquinolinecarboxylic acid, 2-[(2S)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-, 3-[2-[2-(nitrooxy)ethoxy]ethyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811787-49-2 HCAPLUS
CN 3-Isoquinolinecarboxylic acid, 2-[(2S)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-, 3-[2-[[2-(nitrooxy)ethyl]thio]ethyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811787-54-9 HCAPLUS
CN 3-Isoquinolinecarboxylic acid, 2-[(2S)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-, 3-[2-[2-(nitrooxy)ethoxy]ethyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811787-55-0 HCAPLUS
CN 3-Isoquinolinecarboxylic acid, 2-[(2S)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-, 3-[2-[[2-(nitrooxy)ethyl]thio]ethyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811787-60-7 HCAPLUS
CN 1,4-Dithia-7-azaspiro[4.4]nonane-8-carboxylic acid, 7-[(2S)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]-1-oxopropyl]-, 8-[2-[2-(nitrooxy)ethoxy]ethyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811787-61-8 HCAPLUS
CN 1,4-Dithia-7-azaspiro[4.4]nonane-8-carboxylic acid, 7-[(2S)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]-1-oxopropyl]-, 8-[2-[[2-(nitrooxy)ethyl]thio]ethyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811787-67-4 HCAPLUS
CN 6H-Pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid, 9-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]octahydro-10-oxo-, 2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811787-68-5 HCAPLUS
CN 6H-Pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid, 9-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]octahydro-10-oxo-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811787-72-1 HCAPLUS
CN 6H-Pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid, octahydro-9-[[(1S)-1-[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]-3-phenylpropyl]amino]-10-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811787-73-2 HCAPLUS
CN 6H-Pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid, octahydro-9-[[(1S)-1-[[2-[[2-(nitrooxy)ethyl]thio]ethoxy]carbonyl]-3-phenylpropyl]amino]-10-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811787-74-3 HCAPLUS
CN L-Proline, N-[(1S)-1-[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]-3-phenylpropyl]-L-alanyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811786-60-4
CMF C22 H31 N3 O9

Absolute stereochemistry.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 812681-86-0 HCAPLUS
CN Cyclopenta[b]pyrrole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-, 2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 812681-87-1 HCAPLUS
CN Cyclopenta[b]pyrrole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 812681-91-7 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-, 2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 812681-92-8 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 812681-96-2 HCAPLUS
CN Cyclopenta[b]pyrrole-2-carboxylic acid, octahydro-1-[(2S)-2-[[(1S)-1-[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]-3-phenylpropyl]amino]-1-oxopropyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 812681-97-3 HCAPLUS
CN Cyclopenta[b]pyrrole-2-carboxylic acid, octahydro-1-[(2S)-2-[[(1S)-1-[[2-[[2-(nitrooxy)ethyl]thio]ethoxy]carbonyl]-3-phenylpropyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 812682-01-2 HCAPLUS
CN 1H-Indole-2-carboxylic acid, octahydro-1-[(2S)-2-[[(1S)-1-[[2-[2-(nitrooxy)ethoxy]ethoxy]carbonyl]-3-phenylpropyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 812682-02-3 HCAPLUS
CN 1H-Indole-2-carboxylic acid, octahydro-1-[(2S)-2-[[(1S)-1-[[2-[[2-(nitrooxy)ethyl]thio]ethoxy]carbonyl]-3-phenylpropyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 812682-06-7 HCAPLUS
CN Cyclopenta[b]pyrrole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]-1-oxopropyl]octahydro-, 2-[2-[2-(nitrooxy)ethoxy]ethyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 812682-07-8 HCAPLUS
CN Cyclopenta[b]pyrrole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]-1-oxopropyl]octahydro-, 2-[2-[[2-(nitrooxy)ethyl]thio]ethyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 812682-11-4 HCAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(2S)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]-1-oxopropyl]octahydro-, 2-[2-[2-(nitrooxy)ethoxy]ethyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L13 ANSWER 20 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 803728-74-7P 803728-75-8P 803728-76-9P
803728-77-0P 803728-78-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of nitrooxy derivs. of fluvastatin, pravastatin, cerivastatin, atorvastatin and rosuvastatin as

cholesterol-reducing agents with improved anti-inflammatory, antithrombotic and anti-platelet activity)

RN 803728-74-7 HCAPLUS

CN 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, 2-[2-(nitrooxy)ethoxy]ethyl ester, (βR,δR,1S,2S,6S,8S,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 803728-75-8 HCAPLUS

CN 6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-, 2-[2-(nitrooxy)ethoxy]ethyl ester, (3R,5S,6E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



RN 803728-76-9 HCAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, 2-[2-(nitrooxy)ethoxy]ethyl ester, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 803728-77-0 HCAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, 2-[2-(nitrooxy)ethoxy]ethyl ester, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 803728-78-1 HCAPLUS
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, 2-[2-(nitrooxy)ethoxy]ethyl ester, (βR,δR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 21 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 754241-98-0P 754241-99-1P 754242-00-7P
754242-02-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nitric oxide releasing prodrugs of diarylfuranones as selective COX-2 inhibitors)
RN 754241-98-0 HCAPLUS
CN Benzeneacetic acid, α-[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 6-(nitrooxy)hexyl ester, (αZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 754241-99-1 HCAPLUS
CN Glycine, (2Z)-2-[4-(methylsulfonyl)phenyl]-4-[[6-(nitrooxy)hexyl]oxy]-4-oxo-3-phenyl-2-butenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 754242-00-7 HCAPLUS
CN Benzeneacetic acid, α-[2-(acetyloxy)-1-[4-(methylsulfonyl)phenyl]ethylidene]-, 5-(nitrooxy)pentyl ester, (αZ)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 754242-02-9 HCAPLUS
CN Glycine, (2Z)-2-[4-(methylsulfonyl)phenyl]-4-[[6-(nitrooxy)hexyl]oxy]-4-oxo-3-phenyl-2-butenyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 754242-09-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of nitric oxide releasing prodrugs of diarylfuranones as selective COX-2 inhibitors)
RN 754242-09-6 HCAPLUS
CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-, (2Z)-2-[4-(methylsulfonyl)phenyl]-4-[[6-(nitrooxy)hexyl]oxy]-4-oxo-3-phenyl-2-butenyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L13 ANSWER 22 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 174454-43-4P
RL: IMF (Industrial manufacture); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(manufacturing process for NO-donating compds. such as NO-donating diclofenac)
RN 174454-43-4 HCAPLUS
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



L13 ANSWER 23 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 646509-36-6P, 2-[[2-(Nitrooxy)ethyl]thio]ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-38-8P, 2-[[2-(Nitrooxy)ethyl]sulfonyl]ethyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646509-39-9P 646510-12-5P, [[[2-(Nitrooxy)ethyl]oxy]carbonyl]methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646510-17-0P, [[[2-[[2-(Nitrooxy)ethyl]sulfonyl]ethyl]oxy]carbonyl]methyl (2S)-2-(6-methoxy-2-naphthyl)propanoate 646511-47-9P, [[[2-(Nitrooxy)ethyl]oxy]carbonyl]methyl 2-(6-methoxy-2-naphthyl)propanoate 646511-50-4P, [[[2-[[2-(Nitrooxy)ethyl]sulfonyl]ethyl]oxy]carbonyl]methyl 2-(6-methoxy-2-naphthyl)propanoate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of naproxen-derived nitrosated antiinflammatory compds.)
RN 646509-36-6 HCAPLUS
CN 2-Naphthaleneacetic acid, 6-methoxy-α-methyl-, 2-[[2-

(nitrooxy)ethyl]thio]ethyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646509-38-8 HCAPLUS
CN 2-Naphthaleneacetic acid, 6-methoxy-α-methyl-, 2-[[2-(nitrooxy)ethyl]sulfonyl]ethyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646509-39-9 HCAPLUS
CN 2-Naphthaleneacetic acid, 6-methoxy-α-methyl-, 2-[[2-(nitrooxy)ethyl]sulfinyl]ethyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646510-12-5 HCAPLUS
CN 2-Naphthaleneacetic acid, 6-methoxy-α-methyl-, 2-[2-(nitrooxy)ethoxy]-2-oxoethyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646510-17-0 HCAPLUS
CN 2-Naphthaleneacetic acid, 6-methoxy-α-methyl-, 2-[2-[[2-(nitrooxy)ethyl]sulfonyl]ethoxy]-2-oxoethyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646511-47-9 HCAPLUS
CN 2-Naphthaleneacetic acid, 6-methoxy-α-methyl-, 2-[2-(nitrooxy)ethoxy]-2-oxoethyl ester (9CI) (CA INDEX NAME)



RN 646511-50-4 HCAPLUS
CN 2-Naphthaleneacetic acid, 6-methoxy-α-methyl-, 2-[2-[[2-(nitrooxy)ethyl]sulfonyl]ethoxy]-2-oxoethyl ester (9CI) (CA INDEX NAME)



L13 ANSWER 24 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 174454-43-4 174454-49-0 311336-59-1
569371-19-3 639067-57-5
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral pharmaceutical liquid drugs containing nitrate ester NSAIDs having improved bioavailability)
RN 174454-43-4 HCAPLUS
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



RN 174454-49-0 HCAPLUS
CN 1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro-, 2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)



RN 311336-59-1 HCAPLUS
CN Benzeneacetic acid, 3-benzoyl-α-methyl-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



RN 569371-19-3 HCAPLUS
CN Benzoic acid, 2-(acetyloxy)-, 2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)



RN 639067-57-5 HCAPLUS
CN 2-Naphthaleneacetic acid, 6-methoxy-α-methyl-, 2-[2-(nitrooxy)ethoxy]ethyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 25 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 634878-45-8 634878-46-9 634878-50-5
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors)
RN 634878-45-8 HCAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester (9CI) (CA INDEX NAME)



RN 634878-46-9 HCAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl-, 2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)



RN 634878-50-5 HCAPLUS
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl-, 2-[[2-(nitrooxy)ethyl]sulfonyl]ethyl ester (9CI) (CA INDEX NAME)



L13 ANSWER 26 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 174454-43-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nitrooxy derivs. of antiinflammatory/analgesic compds. for treatment of arthritis)
RN 174454-43-4 HCAPLUS
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



L13 ANSWER 27 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 174454-43-4
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nitric oxide-donating NSAIDS adsorbed into carrier particles)
RN 174454-43-4 HCAPLUS
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



L13 ANSWER 28 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 586350-46-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(preparation of nitrate prodrugs for treating or preventing inflammatory, ischemic, degenerative, and proliferative diseases)
RN 586350-46-1 HCAPLUS
CN Riboflavin, 2',3',4'-triacetate 5'-[4-(nitrooxy)butanoate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 29 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 569371-19-3, NCX 4018
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nitric oxide-donating non-steroidal anti-inflammatory drugs)
RN 569371-19-3 HCAPLUS
CN Benzoic acid, 2-(acetyloxy)-, 2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)



L13 ANSWER 30 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 174454-43-4 311336-59-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(self emulsifying drug delivery system containing NSAIDs)
RN 174454-43-4 HCAPLUS
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



RN 311336-59-1 HCAPLUS
CN Benzeneacetic acid, 3-benzoyl-α-methyl-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



L13 ANSWER 31 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 174454-43-4 174454-51-4 311336-59-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing NO-releasing NSAID and surfactants)
RN 174454-43-4 HCAPLUS
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



RN 174454-51-4 HCAPLUS
CN 2-Naphthaleneacetic acid, 6-methoxy-α-methyl-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



RN 311336-59-1 HCAPLUS

CN Benzeneacetic acid, 3-benzoyl-α-methyl-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



L13 ANSWER 32 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 174454-43-4 174454-51-4 311336-59-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(self emulsifying drug delivery system)
RN 174454-43-4 HCAPLUS
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



RN 174454-51-4 HCAPLUS
CN 2-Naphthaleneacetic acid, 6-methoxy-α-methyl-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



RN 311336-59-1 HCAPLUS
CN Benzeneacetic acid, 3-benzoyl-α-methyl-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



L13 ANSWER 33 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 326850-35-5P 326850-41-3P 326850-45-7P
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction)
RN 326850-35-5 HCAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(2R)-aminophenylacetyl]amino]-3,3-dimethyl-7-oxo-, 2-[2-(nitrooxy)ethoxy]ethyl ester, (2S,5R,6R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 326850-41-3 HCAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, 2-[[2-(nitrooxy)ethyl]thio]ethyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 326850-45-7 HCAPLUS
CN Butanedioic acid, 1-[5-(2,5-dihydro-5-oxo-3-furanyl)-3-methyl-2-benzofuranyl]ethyl 2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

IT 326850-53-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction)
RN 326850-53-7 HCAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(2R)-[[(1,1-dimethylethoxy)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, 2-[2-(nitrooxy)ethoxy]ethyl ester, (2S,5R,6R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 34 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 174454-43-4 174454-51-4 311336-59-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of Helicobacter pylori infections with nitric oxide-releasing NSAIDs and proton pump inhibitors)
RN 174454-43-4 HCAPLUS
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



RN 174454-51-4 HCAPLUS
CN 2-Naphthaleneacetic acid, 6-methoxy-α-methyl-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



RN 311336-59-1 HCAPLUS
CN Benzeneacetic acid, 3-benzoyl-α-methyl-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



L13 ANSWER 35 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 158475-26-4
RL: POL (Pollutant); PRP (Properties); OCCU (Occurrence)
(atmospheric thermal stability of peroxynitrates)
RN 158475-26-4 HCAPLUS
CN Peroxynitric acid, 1-(acetyloxy)ethyl ester (9CI) (CA INDEX NAME)



L13 ANSWER 36 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 183195-04-2P 183195-06-4P 183195-07-5P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of nitric esters of 2-(2,6-dihalophenylamino)phenylacetoxyacetic acid derivs.)

RN 183195-04-2 HCAPLUS
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, 2-[2-(nitrooxy)ethoxy]-2-oxoethyl ester (9CI) (CA INDEX NAME)



RN 183195-06-4 HCAPLUS
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, 2-[3-(nitrooxy)propoxy]-2-oxoethyl ester (9CI) (CA INDEX NAME)



RN 183195-07-5 HCAPLUS
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, 2-[4-(nitrooxy)butoxy]-2-oxoethyl ester (9CI) (CA INDEX NAME)



L13 ANSWER 37 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 174454-43-4P 174454-48-9P 174454-49-0P
174454-50-3P 174454-51-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl nitrate ester compds. having antiinflammatory ans well as analgesic and antithrombotic activities)
RN 174454-43-4 HCAPLUS
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



RN 174454-48-9 HCAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 2-fluoro-, 2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)



RN 174454-49-0 HCAPLUS
CN 1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro-, 2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)



RN 174454-50-3 HCAPLUS
CN 2-Thiopheneacetic acid, 5-benzoyl-α-methyl-, 2-[2-(nitrooxy)ethoxy]ethyl ester (9CI) (CA INDEX NAME)



RN 174454-51-4 HCAPLUS

CN 2-Naphthaleneacetic acid, 6-methoxy-α-methyl-, 2-[2-(nitrooxy)ethoxy]ethyl ester (CA INDEX NAME)



L13 ANSWER 38 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 158475-26-4, 1-Acetoxyethyl peroxynitrate
RL: PRP (Properties); RCT (Reactant); RACT (Reactant or reagent)
(thermolysis kinetics of)
RN 158475-26-4 HCAPLUS
CN Peroxynitric acid, 1-(acetyloxy)ethyl ester (9CI) (CA INDEX NAME)



L13 ANSWER 39 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 87055-56-9P 87055-57-0P
RL: RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(formation and alcoholysis of)
RN 87055-56-9 HCAPLUS
CN Peroxynitric acid, 1-(acetyloxy)-2-nitroethyl ester (9CI) (CA INDEX NAME)



RN 87055-57-0 HCAPLUS
CN Peroxynitric acid, 2-nitro-1-(1-oxopropoxy)ethyl ester (9CI) (CA INDEX NAME)



IT 87055-58-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and alcoholysis of)
RN 87055-58-1 HCAPLUS
CN Butanoic acid, 2-nitro-1-(nitrodioxy)ethyl ester (9CI) (CA INDEX NAME)



L13 ANSWER 40 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 39128-70-6P 39128-72-8P 39128-73-9P
39128-74-0P 39128-75-1P 39128-76-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)
RN 39128-70-6 HCAPLUS
CN Peroxynitric acid, 1-[(acetyloxy)methyl]-2-nitroethyl ester (9CI) (CA INDEX NAME)



RN 39128-72-8 HCAPLUS
CN Acetic acid, trifluoro-, 3-nitro-2-(nitrodioxy)propyl ester (9CI) (CA INDEX NAME)



RN 39128-73-9 HCAPLUS
CN Peroxynitric acid, 1-[(acetyloxy)methyl]-1-methyl-2-nitroethyl ester (9CI) (CA INDEX NAME)



RN 39128-74-0 HCAPLUS
CN Peroxynitric acid, 1-(nitromethyl)-2-(1-oxopropoxy)ethyl ester (9CI) (CA INDEX NAME)



RN 39128-75-1 HCAPLUS
CN Heptanoic acid, 3-nitro-2-(nitrodioxy)propyl ester (9CI) (CA INDEX NAME)



RN 39128-76-2 HCAPLUS
CN Peroxynitric acid, 1-[(benzoyloxy)methyl]-2-nitroethyl ester (9CI) (CA INDEX NAME)



L13 ANSWER 41 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 51729-40-9
RL: USES (Uses)
(propellants, with smoldering and combustive action for pulsed combustion)
RN 51729-40-9 HCAPLUS
CN 2-Propenoic acid, butyl ester, polymer with ethenylbenzene and 2-[2-(nitrooxy)ethoxy]ethyl 2-propenoate (9CI) (CA INDEX NAME)

CM 1

CRN 51729-39-6
CMF C7 H11 N O6



CM 2

CRN 141-32-2
CMF C7 H12 O2



CM 3

CRN 100-42-5
CMF C8 H8



L13 ANSWER 42 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 51960-78-2
RL: USES (Uses)
(propellants, pulsating)
RN 51960-78-2 HCAPLUS
CN 2-Propenoic acid, 2-[2-(nitrooxy)ethoxy]ethyl ester, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 51729-39-6
CMF C7 H11 N O6



L13 ANSWER 43 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 39128-70-6 39128-72-8 39128-73-9
39128-74-0 39128-75-1 39128-76-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with nitrogen oxide)
RN 39128-70-6 HCAPLUS
CN Peroxynitric acid, 1-[(acetyloxy)methyl]-2-nitroethyl ester (9CI) (CA INDEX NAME)



RN 39128-72-8 HCAPLUS
CN Acetic acid, trifluoro-, 3-nitro-2-(nitrodioxy)propyl ester (9CI) (CA INDEX NAME)



RN 39128-73-9 HCAPLUS
CN Peroxynitric acid, 1-[(acetyloxy)methyl]-1-methyl-2-nitroethyl ester (9CI) (CA INDEX NAME)



RN 39128-74-0 HCAPLUS
CN Peroxynitric acid, 1-(nitromethyl)-2-(1-oxopropoxy)ethyl ester (9CI) (CA INDEX NAME)



RN 39128-75-1 HCAPLUS
CN Heptanoic acid, 3-nitro-2-(nitrodioxy)propyl ester (9CI) (CA INDEX NAME)



RN 39128-76-2 HCAPLUS
CN Peroxynitric acid, 1-[(benzoyloxy)methyl]-2-nitroethyl ester (9CI) (CA INDEX NAME)



L13 ANSWER 44 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 119247-83-5
(Derived from data in the 6th Collective Formula Index (1957-1961))
RN 119247-83-5 HCAPLUS
CN Diethylene glycol, acetate, nitrate (6CI) (CA INDEX NAME)



L13 ANSWER 45 OF 45 HCAPLUS COPYRIGHT 2007 ACS on STN
IT 119247-83-5
(Derived from data in the 6th Collective Formula Index (1957-1961))
RN 119247-83-5 HCAPLUS
CN Diethylene glycol, acetate, nitrate (6CI) (CA INDEX NAME)



```
=> fil stng
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                          ENTRY     SESSION
FULL ESTIMATED COST                                       260.25      929.76

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                          ENTRY     SESSION
CA SUBSCRIBER PRICE                                       -35.10      -35.10

FILE 'STNGUIDE' ENTERED AT 22:04:42 ON 20 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Sep 14, 2007 (20070914/UP).

=> d his

     (FILE 'HOME' ENTERED AT 21:58:13 ON 20 SEP 2007)

     FILE 'REGISTRY' ENTERED AT 21:58:34 ON 20 SEP 2007
L1             STRUCTURE UPLOADED
L2          15 S L1
L3         274 S L1 SSS FULL
L4             STRUCTURE UPLOADED
L5           1 S L4
L6           3 S L4 SSS FULL
L7           0 S L3  SUB=L6 FULL
L8             STRUCTURE UPLOADED
L9           0 S L8
L10          2 S L8 SSS FULL
L11          0 S L3  SUB=L10 FULL
L12          0 S L10  SUB=L3 FULL

     FILE 'HCAPLUS' ENTERED AT 22:02:54 ON 20 SEP 2007
L13         45 S L3

     FILE 'STNGUIDE' ENTERED AT 22:04:42 ON 20 SEP 2007
```